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 The mechanisms underlying cellular response to proteasome inhibitors have not been 
clearly elucidated in solid tumor models. Evidence suggests that the ability of a cell to 
manage the amount of proteotoxic stress following proteasome inhibition dictates survival. 
In this study using the FDA-approved proteasome inhibitor bortezomib (Velcade®) in solid 
tumor cells, we demonstrated that perhaps the most critical response to proteasome 
inhibition is repression of global protein synthesis by phosphorylation of the eukaryotic 
initiation factor 2-α subunit (eIF2α). In a panel of 10 distinct human pancreatic cancer cells, 
we showed marked heterogeneity in the ability of cancer cells to induce eIF2α 
phosphorylation upon stress (eIF2α-P); lack of inducible eIF2α-P led to excessive 
accumulation of aggregated proteins, reactive oxygen species, and ultimately cell death. In 
addition, we examined complementary cytoprotective mechanisms involving the activation 
of the heat shock response (HSR), and found that induction of heat shock protein 70 kDa 
(Hsp72) protected against proteasome inhibitor-induced cell death in human bladder cancer 
cells. Finally, investigation of a novel histone deacetylase 6 (HDAC6)-selective inhibitor 
suggested that the cytoprotective role of the cytoplasmic histone deacetylase 6 (HDAC6) in 
response to proteasome inhibition may have been previously overestimated.  
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Chapter 1. INTRODUCTION 
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1. Introduction 
1.1 Chronic stress of cancer cells 
At the most fundamental level, a cancer cell can be understood as aberrant. This 
deviation from normalcy does not come without consequences for the cancer cell; those 
qualities that support hallmarks of the malignant state such as heightened proliferative 
capacity also place an extraordinary burden on the cell’s stress response systems (Figure 
1.1), thus creating a window through which further disruption of intracellular homeostasis 
can preferentially kill some cancer cells over normal cells. This “chronic stress” condition 
was recently outlined by Luo, et. al.(1), describing the non-oncogene addiction of many 
cancers. Stress-response mechanisms, normally serving to help protect cells from insults, are 
pirated by cancer cells to support their malignant phenotype. For instance, HSF1, the master 
regulator of the heat shock response (HSR), which responds to proteotoxic stress in 
particular, has been shown to be required for both genetically and chemically induced 
tumorigenesis in murine models (2, 3). Likewise, upregulation of Nrf2, master regulator of 
the oxidative-stress response, by expression of oncogenes such as K-Ras, B-Raf, and Myc 
was found to play a crucial role in mitigating oncogene-induced oxidative stress and also 
promoted tumorigenesis (4). Further evidence suggests that Ras-driven cancers may also 
require high levels of a catabolic process known as autophagy to prevent metabolic stress 
and maintain energy for continued growth (5). In addition, the prevalence of aneuploidy, or 
abnormal chromosome number, in solid tumors is thought to be responsible for creating an 
elevated level of proteotoxic stress (6).  
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Figure 1.1.Intracellular stresses associated with the malignant phenotype and non-
oncogene addiction. Because of the multitude of genetic changes associated with cancer, 
cancer cells often display heightened dependency on stress response pathways, such as those 
activated by oxidative stress, DNA damage, and heat shock/proteotoxic stress. 
 
*Reprinted from Cell, 130(6), Solimini, NL, Luo, J, Elledge, SJ, Non-oncogene addiction 
and the stress phenotype of cancer cells, 986-988, Copyright (2007), with permission from 
Elsevier. Reference # (3). 
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1.2 Protein quality control and degradation in mammalian cells 
Proteins are the primary functional components of a cell, responsible for everything from 
movement and cell division, to transcription, translation, and DNA repair. In E. coli, it has 
been estimated that intracellular protein concentrations can exceed 300 mg/ml (7), creating 
an extremely crowded working environment that is likely exacerbated in more complex 
mammalian cells. Thus, sophisticated quality control mechanisms to ensure proper protein 
folding and function have evolved, as well as efficient degradation systems to rid the 
nucleus and cytosol from expired and misfolded proteins. These pathways are increasingly 
being considered as novel drug targets in cancer as well as other protein folding diseases 
such as Alzheimer’s, Parkinson’s, and cystic fibrosis. Here I will discuss the primary protein 
quality control/folding network, and then discuss the two major degradation pathways for 
proteins that cannot be rescued. 
1.2.1 The chaperone network 
Newly synthesized polypeptides interact immediately with molecular chaperones, 
termed “heat shock proteins (Hsps)” for their discovery as part of a heat-induced stress 
response (8). Multiple families of heat shock proteins exist within mammalian cells, 
including the HSPA (Hsp70), HSPC (Hsp90), HSPH (Hsp110), DNAJ (Hsp40), and HSPB 
(small Hsp) families. Of these, the Hsp90 and Hsp70 families possess distinct functions and 
represent the major players in the chaperone network. Hsp90 family members primarily 
function to interact with folded substrates and ensure proper maturation, functionality, and 
interactions with other proteins. Hsp90 client proteins number in the hundreds, and include 
numerous oncoproteins such as AKT, HIF1α, MMP2, telomerase, and tyrosine kinases, 
providing the rationale for development of Hsp90 inhibitors in cancer (9). Conversely, 
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Hsp70 family members interact with nascent polypeptides immediately as they are being 
translated to ensure proper folding (10). This folding occurs through an ADP/ATP exchange 
cycle, and is facilitated by co-chaperones (Hsp40, HOP) and nucleotide exchange factors 
(Bag1, Hsp110). Hsp70 family chaperones represent some of the most highly conserved 
proteins in evolution, and are close homologs of the bacterial DnaK chaperone (11). In 
addition to the involvement of both the constitutively expressed Hsc70 and the inducible 
Hsp72 chaperones in the protein folding process, they are essential for preventing 
aggregation and determining the cellular fates of misfolded proteins. The chaperone 
complex senses misfolding by recognizing exposed hydrophobic residues, and then recruits 
specific ubiquitin ligases such as CHIP to promote the attachment of ubiquitin to lysine 
residues on the substrate (12), marking the substrate for degradation by mechanisms 
discussed in further detail below. 
1.2.2 The ubiquitin-proteasome system 
The primary protein degradation system in eukaryotic cells consists of the ubiquitin 
proteasome system (UPS) (Figure 1.2). In this elegant system, a small 7.6-kDa protein 
known as ubiquitin “marks” proteins for degradation (a process henceforth referred to as 
ubiquitylation). Ubiquitylation involves a series of enzymatic steps that first begins with 
ATP-dependent activation, or “charging” of the carboxy-terminus of the ubiquitin molecule 
by E1 ubiquitin-activating enzymes. The activated ubiquitin is then transferred to an E2 
ubiquitin-conjugating enzyme via a thiolester linkage. Finally, the E2 enzyme interacts with 
an E3 ubiquitin-ligase enzyme that is bound to the substrate, and E3 catalyzes the transfer 
of the ubiquitin molecule from the E2 to the substrate (in some cases, ubiquitin can also be 
transferred to the E3 first and then subsequently the substrate). This cycle repeats itself  
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Figure 1.2 The ubiquitin-proteasome pathway. Misfolded proteins are tagged with 
ubiquitin in an ATP-dependent fashion by a series of enzymatic steps, which then marks 
the substrate for degradation and recycling to peptide fragments by the 26S proteasome. 
 
*Reprinted by permission from Macmillan Publishers Ltd: [NATURE 
BIOTECHNOLOGY] (13), copyright (2000). 
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multiple times to form a lysine-linked polyubiquitin chain. Several different lysine residues 
can be used for this linkage, with important functional consequences. Lys48-linked 
ubiquitin polymers most commonly signal proteasomal degradation, whereas Lys63-linked 
polymers have been implicated as signals for the aggresome pathway and autophagy (14). 
Additional ubiquitin polymers have also recently been discovered as markers for 
proteasomal degradation, such as Lys11. Once a Lys48 or Lys11 polyubiquitin chain has 
been attached to a substrate, it is recognized and degraded by the proteasome. The 
proteasome is a barrel-shaped protease that serves as the primary protein degradation 
machine in eukaryotic cells. Abundant in both the cytosol and nucleus, it consists of a 
cylindrical 20S core structure interacting with two 19S regulatory “cap” subunits at both 
ends. Collectively, this structure is referred to as the 26S proteasome. The 19S regulatory 
subunit is responsible for recognizing polyubiquitinated substrates and facilitates the 
unwinding and feeding of the substrate into the proteolytic 20S core in an ATP-dependent 
fashion (15). The proteolytic 20S core contains three different catalytic activities, the 
chymotryptic, the tryptic, and the caspase-like, which together mediate the cleavage of 
peptide bonds between any two amino acids. 
1.2.3 The autophagy-lysosome system  
Whereas the UPS serves as the primary degradation system for individual proteins, 
there also exists an alternative degradation system for bulk substrates such as organelles or 
large protein aggregates. These larger structures are degraded via a process known as 
autophagy, which terminates with the deposit of substrates into acidic, protease filled 
organelles known as lysosomes. Three distinct forms of autophagy exist: macroautophagy, 
microautophagy, and chaperone-mediated autophagy (CMA) (16). Macroautophagy 
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involves the sequestration and degradation of bulk substrates, including organelles and/or 
protein aggregates, and is often activated in response to starvation as a way to recycle 
macromolecules for energy (17).  Conversely, microautophagy refers to the direct 
engulfment of the cytosol by invagination of the lysosomal membrane, whereas CMA refers 
to the transport of individual proteins to lysosomes by molecular chaperones that recognize 
specific KFERQ-like sequences in substrates (18). Importantly, proteasome inhibitors have 
been shown to be potent activators of macroautophagy (hereafter referred to as autophagy), 
and thus this will be the focus of the discussion here (19).   
Autophagy begins with the formation of double-membraned vesicles termed 
autophagosomes, preceded by the recruitment of essential autophagy-related proteins 
(ATGs) to the phagophore-assembly site (PAS). The autophagosome then engulfs the 
substrate via a process facilitated by interactions between a core autophagosomal membrane 
protein, Atg8/LC3, and the autophagy cargo adaptor proteins p62/SQSTM1 and NBR1, 
which interact directly with ubiquitylated aggregates and present them to the autophagic 
membranes (20-22). Autophagosomes are then transported along the microtubule network, 
potentially through interactions with histone deacetylase 6 (HDAC6), to lysosomes for 
degradation of their contents. Once within the acidic environment of the lysosome, 
substrates are catabolized and translocated back out into the cytosol by lysosomal membrane 
permeases (23). 
1.3 Proteasome inhibitors 
Proteasome inhibitors were initially introduced as useful tools for biologists studying 
translation and degradation of particular proteins of interest, akin to other cell biology tools 
such as cycloheximide (a translation inhibitor) and actinomycin D (a transcription inhibitor). 
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These early inhibitors included peptide aldehydes (MG-132) and vinyl sulfones, as well as 
natural products such as β-lactones (lactacystin) and epoxyketones (epoxomicin). These 
inhibitors function in a similar fashion, forming covalent bonds with the catalytic threonine 
residue in the β5 chymotryptic-like site of the proteasome. These covalent interactions 
prevent nucleophilic attack on peptide bonds by the catalytic threonine residue, and block 
substrate cleavage. However, many of these compounds (with the exception of 
epoxyketones) produce undesirable off-target inhibition of other proteases such as 
cathepsins and calpains. In the late 1990’s, the peptide aldehydes were modified by Julian 
Adams and colleagues to contain a boronate group, resulting in a novel class of potent, 
selective, and reversible inhibitors of the proteasome (24). The lead compound identified 
from these studies, PS-341, later became the first FDA- approved proteasome inhibitor for 
cancer therapy (specifically in multiple myeloma and mantle cell lymphoma), and is 
currently referred to as bortezomib, or Velcade® (25). Other PIs have since been developed, 
including marizomib, also known as salinosporamide A or NPI-0052 (Nereus 
Pharmaceuticals, Inc.) (26, 27) and carfilzomib or PR-171 (Proteolix, Inc.) (28). These new 
PIs offer irreversible inhibition of the proteasome and potentially higher systemic levels of 
sustained proteasome inhibition in patients.  Clinical trials across several tumor sites are 
now ongoing using next generation PIs. In the following text, key cellular responses to 
proteasome inhibition will be discussed, as well as potential mechanisms mediating their 
toxicity in cancer cells, with a particular emphasis on bortezomib. 
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Figure 1.3 The proteasome: structure and mechanism. A) The complete 26S proteasome, 
B) The 20S core subunit, C) The catalytic mechanism of proteasome-mediated peptide 
cleavage. 
*Reprinted from Chemistry & Biology, 19(1), Kisselev, AF, van der Lindin, WA, 
Overkleeft, HS, Proteasome inhibitors: An expanding army attacking a unique target. 
Copyright (2012), with permission from Elsevier. Reference #(29) 
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1.3.1 Cellular responses to proteasome inhibitors 
1.3.1a The heat shock response 
 The heat shock response (HSR) is a highly conserved cytoprotective pathway 
involving the upregulation of molecular chaperones that is activated by proteotoxic stress in 
the cytosol. This can be caused by numerous stressors, including heat, heavy metals, 
arsenicals, viral and bacterial infections, and reactive oxygen species (30, 31). Importantly, 
numerous studies have demonstrated that proteasome inhibitors are potent inducers of the 
HSR (32-34). The HSR is regulated in eukaryotes by a family of transcription factors known 
as heat shock factors (HSFs). In mammalian cells, there exist three different isoforms 
(HSF1, 2, 4), with HSF1 being the dominant regulator of the stress-induced HSR (35).  
Under resting conditions, HSF1 exists as an inactive monomer bound by Hsp90 and/or 
Hsc70 and histone deacetylase 6 (HDAC6), a ubiquitin-binding protein deacetylase, in a 
repressive complex. Upon proteotoxic stress, misfolded proteins compete away the 
chaperones and HDAC6, leaving HSF1 free to trimerize and attain transcriptional activity. 
Activation of HSF1 also involves extensive post-translational modifications, including 
phosphorylation at multiple serine residues (36), with more recent evidence pointing to roles 
for acetylation (37) and sumoylation (38) in regulating HSF1 trans-activity. Activated HSF1 
binds to specific sequences known as heat shock elements (HSE) in the promoters of target 
genes and drives transcription, often with the help of co-regulators (39). The target genes of 
HSF1 include the inducible chaperones of the Hsp70 (HSPA1A/HSPA1B), Hsp40 
(DNAJB1), and small Hsp families (Hsp27/HSPB1), which serve to immediately cope with 
misfolded protein stress. Importantly, inducible Hsp70 and Hsp40 provide a negative 
feedback loop for “turning off” HSF1; once a sufficient amount of these chaperones are 
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present to restore proteostasis, they bind directly to HSF1’s transactivation domain to 
attenuate the HSR (35). Although HSF1 is best known for its role in upregulating molecular 
chaperones, evidence suggests myriad other transcriptional targets (up to 3% of the genome 
in yeast) (40) and genome-wide acetylation (41), pointing to HSF1 as an extensive 
remodeler of the genomic landscape during proteotoxic stress. 
1.3.1b  eIF2α phosphorylation and the integrated stress response (ISR)  
 Mammalian cells retain tight control of protein synthesis during stress. Biologically, 
it makes sense to decrease the volume of new proteins being synthesized when facing a 
stress that is causing a buildup of misfolded proteins, such as proteasome inhibition. The 
primary mechanism used to control translation rates involves inhibitory phosphorylation of 
the eIF2 translation initiation factor at the Ser51 residue of its α subunit (42). In its active, 
unphosphorylated form, eIF2 bound with GTP and the Met-tRNAi assembles with eIF1, 
eIF1A, eIF3, eIF4F, and eIF5 to form the 43S pre-initiation complex. The complex scans the 
5’ cap of the mRNA being translated, and once the start codon is recognized, the eIF2-bound 
GTP is hydrolyzed to GDP and the initiator Met-tRNA binds to the 40S ribosome to provide 
the initial amino acid for the polypeptide (42). Inactivated eIF2-GDP is recycled back to its 
active GTP-bound form by eIF2B, a guanine nucleotide exchange factor (GEF). Upon 
proteotoxic stress, the α subunit of eIF2 is phosphorylated and directly binds to and inhibits 
the nucleotide exchange capacity eIF2B, thus dramatically decreasing eIF2-GTP levels and 
reducing translation rates. 
 Phosphorylation of eIF2α is mediated by four known stress-activated kinases in 
mammalian cells: HRI (EIF2AK1), PKR (EIF2AK2), PERK (EIF2AK3), and GCN2 
(EIF2AK4). HRI (heme-regulated inhibitor) is best known for regulating protein synthesis in  
13 
 
 
 
 
 
 
Figure 1.4. Schematic of stress-mediated translational repression by eIF2α 
phosphorylation. Stress (proteotoxic, viral, nutrient, hypoxic, hypoglycemic) serve to 
directly activate at least one of four known kinases (HRI, GCN2, PERK, or PKR), which 
then phosphorylate eIf2α at the Ser51 residue, effectively shutting off cap-dependent 
translation (protein synthesis). This allows for selective translational upregulation of the 
ATF4 transcription factor, which coordinates an integrated stress response (ISR) to alleviate 
stress. Phospho- eIf2α levels are reduced upon alleviation of stress by GADD34, a 
phosphatase upregulated by ATF4. 
 
*Reprinted from Advances in Cancer Research, 116, David J. McConkey, Matthew C. 
White, Wudan Yan,, Chapter 4 – HDAC inhibitor modulation of proteotoxicity as a 
therapeutic approach in cancer, 131-163, Copyright (2012), with permission from Elsevier. 
Reference # (43). 
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Figure 1.5. Phospho-eIF2α as a key signaling node for sensing multiple different 
stressors. The eIF2α kinases (HRI, GCN2, PKR, PERK) are evolutionarily optimized to 
sense a variety of unique upstream stress signals, but each serve to propagate the same 
downstream signaling event (eIF2α phosphorylation). Conceptually, this points to phospho- 
eIF2α as a “node” that controls protein synthesis and the integrated stress response (ISR) in 
response to multiple stressors. 
 
*Reprinted from Advances in Cancer Research, 116, David J. McConkey, Matthew C. 
White, Wudan Yan,  Chapter 4 – HDAC inhibitor modulation of proteotoxicity as a 
therapeutic approach in cancer, 131-163, Copyright (2012), with permission from Elsevier. 
Reference # (43). 
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erythroid cells in response to iron deficiencies (44); however, it also has been reported to be 
activated by a variety of cytosolic stresses, such as arsenic, heat shock, osmotic stress, and 
importantly, proteasome inhibition (45, 46). Interestingly, HRI appears to exist in a 
repressive complex with cytosolic chaperones (Hsp70), and can be activated when these 
chaperones dissociate to bind accumulating misfolded proteins in the cytosol (47, 48). PKR 
(protein kinase R) contains double-stranded RNA binding motifs, and is directly activated 
by viral infections as well as interferons (49, 50). PERK (PKR-like endoplasmic reticulum 
kinase), as its name suggests, functions exclusively in the ER, existing in a repressive 
complex with the ER chaperone Grp78/BiP until misfolded proteins compete away Grp78 
from PERK, leading to PERK autophosphorylation, dimerization, and activation (51). In 
addition to activation by ER stress, PERK is also activated by glucose deficiency (52). 
Finally, GCN2 (general control nonderepressible 2) is the most highly conserved of these 
kinases (from yeast to mammals), and serves as a sensor of nutrient deprivation. GCN2 is 
activated by amino acid starvation conditions via direct binding of uncharged tRNAs to a 
histidyl-tRNA synthetase-related sequence (HisRS) near its carboxy terminus.  
 While the major function of eIF2α phosphorylation is to shut off global protein 
synthesis, it also works to activate the integrated stress response (ISR) via selective 
translational upregulation of certain mRNAs, such as activating transcription factor 4 
(ATF4). This is accomplished through an elegant mechanism in which reduced amounts of 
active eIF2-GTP allow the scanning ribosome to bypass an inhibitory upstream open reading 
frame (uORF2) in the ATF4 mRNA, and resume translation at the ATF4 protein-encoding 
ORF. This regulatory mechanism resembles that of the yeast GCN4 mRNA and its 
corresponding protein Gcn4p, which serves to upregulate genes involved in amino acid 
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biosynthesis. ATF4 plays a similar but much broader role in mammalian cells by regulating 
expression of numerous stress-response genes involved in amino acid metabolism, protein 
folding, oxidative stress responses, autophagy, and cell death (53, 54). Once the cellular 
stress is resolved, ATF4 also serves to upregulate part of a negative feedback loop involving 
GADD34, a protein phosphatase that dephosphorylates eIF2α and attenuates the ISR, 
Evidence also suggests that under certain conditions, eIF2α phosphorylation can propagate 
cell death through a terminal unfolded protein response (55, 56). A well-known target of the 
ATF4 transcription factor that is translationally upregulated by eIF2α phosphorylation is the 
CHOP/DDIT3/GADD153 transcription factor (hereafter referred to as CHOP). Induction of 
CHOP gene expression is thought to promote apoptosis; studies suggest that this may occur 
through transcriptional binding and upregulation of BIM protein promoter regions (57), or 
through inhibition of Bcl-2 expression. CHOP expression is tightly linked to eIF2α 
phosphorylation, as mutant MEFs expressing a knock-in serine to alanine mutation in eIF2α 
that prevents phosphorylation fail to induce CHOP expression following ER stress (58). 
However, despite the absence of CHOP expression, these mutant cells display heightened 
sensitivity to ER stress, suggesting that CHOP is not required for stress-induced apoptosis, 
and that it may have other important functions that have not been revealed (59). 
1.3.1c Endoplasmic Reticulum (ER) Stress and Unfolded Protein Response (UPR) 
 The endoplasmic reticulum (ER) is responsible for folding of secretory and 
membrane proteins. The ER lumen is uniquely tuned for high-capacity protein folding as an 
oxidative environment, also containing high levels of calcium (Ca2+) and molecular 
chaperones. ER-specific homologs of cytosolic Hsp70 and Hsp90 proteins, Grp78/BiP and 
Grp94, interact with substrates in the lumen to promote proper folding. A multitude of other 
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ER-specific chaperones and folding cofactors are also present: Erdj1-5 (Hsp40 homologs) 
stimulate Grp78 ATP:ADP exchange, calnexin and calreticulin function as lectin chaperones 
for glycans, and protein disulfide isomoerases (PDIs) promote disulfide bond formation. In 
addition to folding, proteins undergo extensive post-translational modifications in the ER, 
such as N-linked glycosylation, carboxylation and hydroxylation of amino acids, and 
attachment of glycosylphosphatidylinositol. Proteins that are unsuccessfully folded are 
transported out of the ER for degradation by the proteasome through the Sec61 pore 
complex via a process called ER-associated degradation (ERAD). Perturbations in the 
folding milieu of the ER lumen are specifically referred to as ER stress and can arise from 
many different cellular insults, such as oxidative stress, low glucose, depletion of luminal 
Ca2+ stores, and inhibition of the 26S proteasome. Several compounds are known inducers of 
ER stress: thapsigargin (TG) blocks the sarcoplasmic reticulum Ca2+ ATPase and results in 
release of ER calcium stores (60), tunicamycin (TM) prevents the first step of protein 
glycosylation within the ER (61), and dithiothreitol (DTT) reduces disulfide bonds within 
the oxidative ER lumen. ER stress is directly sensed by ER chaperones, primarily Grp78, as 
the concentration of misfolded proteins rises. The exposed hydrophobic residues of the 
misfolded substrates competitively inhibit Grp78 binding of three ER transmembrane 
signaling proteins. Once released from Grp78, these proteins become activated via 
autophosphorylation and propagate an elaborate downstream stress response known 
collectively as the unfolded protein response, or UPR. The three arms of the UPR signaling 
apparatus are IRE1, ATF6, and PERK. IRE1 is a transmembrane kinase that is also an 
endonuclease. Upon dimerization and autophosphorylation, IRE1 directly splices the mRNA  
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Figure 1.6 The unfolded protein response (UPR). The accumulation of unfolded proteins 
in the ER activates a three-armed signaling cascade, orchestrated by ATF6, PERK, and 
IRE1, that seeks to restore ER homeostasis. 
 
*Reprinted by permission from Macmillan Publishers Ltd: [EMBO reports], (62), copyright 
(2006).  
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of a key UPR-specific transcription factor known as XBP1, thereby activating XBP1 and 
promoting upregulation of multiple ERAD and ER chaperone genes (Figure 1.3). ATF6 is a 
transcription factor that upon release from Grp78, gets processed into its active form in the 
Golgi apparatus, then translocates to the nucleus where it also upregulates ER chaperones as 
well as the transcription factor CHOP, which may promote apoptosis if the stress is 
unresolved. PERK is a transmembrane kinase that upon Grp78 release forms homodimers 
and undergoes autophosphorylation and activation. Activated PERK phosphorylates the 
cytosolic eukaryotic initiation factor 2 on its α-subunit (eIF2α), which serves to halt global 
protein synthesis and translationally upregulate the ATF4 transcription factor. ATF4 serves 
as a master regulator of the integrated stress response (ISR) (53) by inducing expression of 
genes involved in promoting ER homeostasis, ERAD, and amino acid and antioxidant stress 
responses. ATF4 also upregulates CHOP, which, in addition to its known pro-apoptotic 
functions, also induces expression of the GADD34 phosphatase cofactor that recruits the 
PP1 phosphatase complex to eIF2α to attenuate phosphorylation and restore protein 
synthesis (63). 
1.3.1d Aggresomes and Autophagy 
 Under conditions of extreme proteotoxic stress, such as proteasome inhibition where 
the cell’s primary protein degradation system is compromised, or accumulation/ 
overexpression of mutant aggregate-prone proteins (e.g. CFTR, mutant Huntington), 
additional degradation routes must be exploited. Thus, the autophagy-lysosomal system 
(ALS) is activated in as an alternative mechanism (see Section 1.2.3c). Because the ALS 
functionally differs from the ubiquitin-proteasome system (UPS) in that it targets larger bulk 
substrates as opposed to specific individual proteins, accumulating misfolded proteins 
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coalesce to the microtubule-organizing center (MTOC) to form large aggregates termed 
“aggresomes” that are thought to be novel substrates for autophagy (64). Aggresome 
formation is not random, but rather is an active, multi-stepped process that represents an 
important part of the cytoprotective response to PIs. In the early stages of the aggresome 
pathway, misfolded ubiquitin-tagged proteins that cannot be degraded by the proteasome 
begin to form small aggregates or aggresomal particles through interactions with exposed 
hydrophobic residues. These smaller aggregates are bound by a unique protein deacetylase 
known as HDAC6 (histone deacetylase 6 – see Chp. 5) capable of binding both ubiquitin 
and dynein motors (65). Evidence suggests that the type of polyubiquitin chain, either Lys48 
or Lys63 –linked (K48 and K63, respectively), may be important for HDAC6 recognition and 
recruitment to aggresomes. K48-linked chains are traditionally associated with proteasomal 
degradation because they are more efficiently degraded by proteasomes (66), whereas K63-
linked chains appear to be preferentially recognized by HDAC6 and p62/SQSTM1(p62) and 
facilitate degradation by the aggresome-autophagy pathway (67, 68). These minus-end-
directed dynein motors transport HDAC6 and its bound ubiquitylated substrates along the 
microtubule network from multiple cytosolic locations to a centralized perinuclear region 
near the MTOC (64). It is hypothesized that aggresomes form around the MTOC because 
the peri-centriolar region is enriched in 20S proteasomes, proteasomal activators, and 
molecular chaperones (69, 70). However, clearance of aggresomes formed without the use 
of PIs is only partially inhibited upon the addition of PIs, suggesting that the major route of 
aggresomal clearance is proteasome-independent, regardless of how the aggresome was 
formed. Accordingly, we found that in some solid tumor cells, aggresomes were only seen 
upon dual inhibition of both autophagy and the proteasome (71). In addition, p62/SQSTM1, 
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a ubiquitin-binding cargo-adaptor protein that interacts directly with Atg8/LC3 on 
autophagosome membranes and facilitates autophagic degradation of aggregates, co-
localizes to aggresomes (72, 73). Overall, the data suggest that aggresomes are a unique bulk 
substrate for the ALS. 
1.3.2 Mechanisms of anti-tumor activity 
Because of the myriad intracellular consequences of proteasome inhibition, it has 
been difficult to conclusively determine how PIs kill cancer cells. Here, we discuss several 
of the most promising hypotheses. In a broad sense, much of the original rationale for 
investigating proteasome inhibitors as anti-cancer agents stemmed from knowledge of the 
proteasome’s central role coordinating the cell cycle and mitosis through degradation of cell 
cycle regulators (24). In addition to cell cycle regulation, the proteasome was also found to 
control the activity of NFκB, a pro-survival transcription factor associated with 
inflammatory stimuli and thought to promote the viability of cancer cells (74). The 
proteasome controls NFκB activity through degradation of an endogenous inhibitor of NFκB 
known as IκBα, which when bound to NFκB, prevents translocation into the nucleus and 
blocks transcriptional activity (75). However, upon phosphorylation by IKK, IκBα is 
ubiquitylated and degraded by the proteasome, thus activating NFκB.  NFκB is activated at 
high levels in MM and pancreatic cancer, and is known to prevent apoptosis (76, 77). This 
provided enthusiasm and rationale for the use of PIs as NFκB inhibitors in cancer; however, 
later studies using selective inhibitors of the IKK kinase (PS-1145) proved that direct 
inhibition of NFκB was much less cytotoxic than bortezomib (76, 78), suggesting that PI-
induced cell-killing was not driven by NFκB inhibition.  
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The proteasome is also essential for controlling levels of proteins associated with 
apoptosis, another potential explanation for the anti-tumor effects of PIs. For example, 
bortezomib stabilizes the pro-apoptotic BH3-only protein Bim, and this was found to be 
required for reversal of paclitaxel resistance by bortezomib (79). In colon, lung, and ovarian 
carcinomas, bortezomib was found to promote accumulation of another BH3-only protein 
Bik, but not other members of the BCL-2 family (Bak, Bax, Bcl-XL, Bcl-2), and increased 
levels of Bik correlated with sensitivity to bortezomib (80). Perhaps the most consistent 
effect of PIs on pro-apoptotic BH3-only proteins is the induction of Noxa expression both at 
the mRNA and protein levels. High-doses of PS-341 (now bortezomib) were shown to cause 
Noxa-dependent cell death in squamous cell carcinoma. In this study, the authors also found 
that Noxa upregulation appeared to be dependent on eIF2α phosphorylation and the UPR 
(81). Similar results were also found in melanoma and myeloma cells, where the PIs MG-
132, lactacystin, and bortezomib all increased Noxa transcript and protein levels, and 
siRNA-mediated knockdown of Noxa significantly reduced cell death in response to all 
three agents (82). 
As previously discussed, the proteasome is the backbone of intracellular protein 
degradation. More compelling, perhaps, than the stabilization/accumulation of individual 
proteins are the effects of PIs on proteins en masse. In broad terms, inhibition of the 
proteasome immediately blocks the route of choice for misfolded and expired proteins, for 
which removal is a significant task for the cell (new synthesis alone is estimated to be ~30% 
defective) (83, 84). Thus, perhaps the strongest hypothesis for PI-induced toxicity suggests 
that the buildup of misfolded and aggregating proteins is the toxic event that kill cells. 
Evidence from MM supports this concept of PI-induced proteotoxicity. Obeng, et. al. 
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demonstrated that PIs caused a “terminal” UPR in MM cells that seemed to correlate with 
high amounts of immunoglobulin (IgG) retention (55). Furthermore, Meister, et. al. used an 
elegant model system in which subclones of MM cells were manipulated to either express 
low or high levels of IgG, and found that increased IgG production sensitized the subclones 
to bortezomib (85). Indeed, the physiologic role of normal plasma cells (antibody 
production) requires an extensive ER-Golgi network, and MM cells usually retain this 
“hard-wiring” for protein production and secretion. Overall, the robust clinical activity of 
bortezomib (clinically Velcade®) in MM supports the idea that proteotoxic stress dictates 
the anti-tumor activity of PIs. Our data discussed in Chapter 3 with respect to eIF2α-P and 
protein aggregation also provide strong evidence in support of this mechanism of action for 
PIs. 
Recently, another intriguing explanation for PI-induced cell death was outlined (86). 
Here, Suraweera, et al. proposed that PIs severely deplete amino acid pools, which elicits a 
GCN2- eIF2α-P- mediated stress response culminating in CHOP production and ultimately 
cell death. By supplementing cells with cysteine and/or asparagine/aspartate, they were able 
to rescue cells from bortezomib-induced death. However, cysteine is a known anti-oxidant, 
which could be an alternative explanation for its protective capabilities (see Chapter 3 for 
data/discussion on the role of ROS production in PI-induced cell death). Because the 
proteasome generates a significant amount of free amino acids through the recycling of 
peptides (15), this is an attractive hypothesis that bears further exploration. Indeed, the 
proteasomal generation of amino acids was found to be required for protein synthesis under 
conditions of nutrient restriction in HeLa cells (87). It is therefore conceivable that blocking 
the proteasome perturbs the free amino acid pool to an extent that activates GCN2, 
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especially in cancer cells which often have higher rates of protein synthesis than normal 
cells (88).  
1.4 Summary and scope of dissertation 
 In this dissertation, I seek to better understand how molecular heterogeneity among 
cancer cells influences response to the proteasome inhibitor bortezomib. Here, I present 
three separate but related research projects evaluating different components of the PI-
induced stress response and determining each of their respective contributions to cancer cell 
survival. First, in Chapter 3, I highlight the central role of HRI activation and eIF2α-P in 
protecting pancreatic cancer cells from BZ-induced cell death. This represents the first such 
study evaluating heterogeneous eIF2α-P in solid tumor cells, and the first to suggest that this 
correlates with BZ sensitivity. In Chapter 4, I demonstrate that Hsp72 induction protects 
bladder cancer cells from BZ, and for the first time outline that heterogeneity exists among 
bladder cancer cells in both basal and inducible Hsp72 expression that is associated with 
Hsp72 (HSPA1A) promoter methylation. Finally, in Chapter 5, I evaluated a novel HDAC6-
selective inhibitor in pancreatic and bladder cancer cells through a series of in vitro tests, 
demonstrating inhibitor specificity at low micro-molar doses as well as investigating its 
potential for combination therapy with BZ.  
 In multiple myeloma, where PIs are frontline therapy, response rates to Velcade® are 
only ~35-40% (89), meaning that roughly 60% of patients do not respond. Lymphomas 
(mantle cell lymphomas, indolent non-Hodgkin’s, refractory B-cell non-Hodgkin’s) 
typically show response rates up to 45-60% (90, 91).  In solid tumors, less impressive 
response rates have been seen thus far (92), with non-small cell lung cancer (NSCLC) 
responding at around 8% (93), with minimal responses in melanoma (94), recurrent glioma 
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(95), and metastatic breast cancer (96). As such, there is much need for a better 
understanding of how molecular heterogeneity among tumor cells can influence response to 
PIs, and this dissertation seeks to make a valuable contribution towards this aim. 
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Chapter 2. MATERIALS AND METHODS 
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2.1 Materials and Methods for Chapter 3 
2.1.1 Cell lines and culture - HPDE immortalized pancreatic ductal epithelial cells were a 
gift from Dr. Craig Logsdon (Department of Cancer Biology, U.T. M.D. Anderson Cancer 
Center). BxPC3, Panc1, HS766t, MiaPaCA-2, and CF-Pac1 pancreatic cancer cells were 
obtained from ATCC (American Type Culture Collection, Manassas, VA). Suit2, SU86.86, 
and T3M4 pancreatic cancer cells were obtained from Eric Collisson (UCSF).  mPanc96 
pancreatic cancer cells are a genetically identical but phenotypically distinct variant of 
AsPC1 cells. The identities of all of the human cell lines were validated by DNA 
fingerprinting, performed in the MD Anderson Characterized Cancer Cell Line Core. All 
pancreatic cancer cells (except for BxPC3) were maintained in DMEM supplemented with 
10% fetal bovine serum (HyClone/Thermo Scientific, Waltham, MA), MEM vitamins, 
sodium pyruvate (Mediatech/Corning Cellgro, Manassas, VA), L-glutamine, non-essential 
amino acids, Penicillin/Streptomycin (Lonza, Switzerland), and HEPES. BxPC3 cells were 
cultured in RPMI-1640 supplemented with 10% fetal bovine serum (HyClone/ Thermo 
Scientific), MEM vitamins, L-glutamine, sodium pyruvate, non-essential amino acids, 
Penicillin/Streptomycin, and HEPES. HPDE cells were maintained in serum-free 
keratinocyte media supplemented with EGF and BPE (Gibco/Life Technologies, Grand 
Island, NY). Wild-type eIF2α51SS and eIF2α51AA knock-in mutant MEFs were obtained from 
Dr. David Ron (NYU/ University of Cambridge) and grown as described previously (71). 
All cells were grown in a humidified incubator at 37° C under an atmosphere of 5% CO2 in 
air.  
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2.1.2 Chemicals and antibodies - Bortezomib was purchased from ChemieTek (Indianapolis, 
IN). Thapsigargin, cycloheximide, and propidium iodide (PI) and N-acetyl-L-cysteine 
(NAC) were purchased from Sigma-Aldrich (St. Louis, MO). Antibodies were purchased 
from the following sources: phospho-eIF2α, GCN2, PERK and lamin A/C (Cell Signaling 
Technology, Beverly, MA), eIF2α, (Invitrogen/Life Technologies, Grand Island, NY), HRI 
and ubiquitin (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-GCN2 (Abcam, 
Cambridge, MA), LC3 (MBL International, Woburn, MA), β-actin (Sigma-Aldrich), and 
anti-mouse/ anti-rabbit HRP-labeled secondary antibodies (Promega, Madison, WI). 
2.1.3 Immunoblotting – Cells (~70% confluency) were collected via scraping on ice, and 
lysed by vigorous vortexing using a 1% NP-40 buffer containing 50mM Tris-HCl (pH 7.4), 
150mM NaCl, 5mM EDTA, 0.1% Triton X-100, 25mM NaF, 100mM Na3OV4, 10mM 
glycerophosphate, 10mM PMSF, and complete protease inhibitors. Lysates were clarified by 
centrifugation and then protein concentrations were quantified using a commercial Bradford 
assay (Bio-Rad, Hercules, CA). Equal amounts of protein (15-20μg) were separated by 6-
10% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked 
with either 5% bovine serum albumin (BSA) or 5% nonfat dried milk dissolved in TBS-T, 
then probed overnight in the same solutions with primary antibodies. Membranes were then 
washed and incubated with species-specific horseradish peroxidase-labeled secondary 
antibodies. Immunoblots were developed by chemiluminescence (GE Healthcare Life 
Sciences, Piscataway, NJ), and densitometry was performed using ImageJ. 
2.1.4 Measurement of cell viability - Cells were plated in 6-well plates and allowed to attach 
overnight. Cells (~40-60% confluency) were then exposed to drugs for 48 hours and 
collected by trypsinization. Cell pellets were washed once in PBS and then resuspended in 
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0.5mL of fresh PBS. Propidium-iodide (PI) solution (100μg/mL) was added in a 1:10 
dilution immediately prior to analyzing the samples. PI–positive (non-viable) cells were 
measured by FACS (fluorescence activated cell sorting) analysis on the FL3 channel of a 
Beckman Coulter FC500 flow cytometer. 
2.1.5 3H-leucine incorporation assays – Equal numbers of cells were plated in 6-well plates 
(~2-3 x 105 cells/well) and allowed to attach overnight.  Cells were exposed to bortezomib 
(30nM) or cycloheximide (20μM) as indicated. Following incubation, drugs were removed 
and cells were pulsed for 1-2 hours with 1 μCi/mL L-[4,5- 3H(N)] leucine (Perkin-Elmer, 
Waltham, MA) in leucine-free media (MP Biomedicals, Solon, OH) supplemented with 10% 
dialyzed FBS, vitamins, L-glutamine, antibiotics, and HEPES. Cells were trypsinized and 
pellets lysed in a 1% Triton X-100 buffer containing 25mM Tris-HCl, 300mM NaCl, and 
10mM PMSF plus complete protease inhibitors by rotation for 20-30 minutes at 4˚ C. 
Lysates were clarified via centrifugation and proteins were precipitated overnight at 4˚ C in 
5% trichloroacetic acid (TCA). The resulting precipitates were collected via centrifugation 
and dissolved in 0.1% KOH. Samples were aliquoted in triplicate and combined with 
scintillation fluid (ThermoFisher Scientific, Waltham, MA). CPMs were measured by a 
Beckman Coulter LS6500 scintillation counter. 
2.1.6 Leucine deprivation – Following overnight attachment, complete DMEM was removed 
from cells and cells were washed 1x in PBS. Leucine-free media (see above) was added for 
2 hours prior to harvesting. 
2.1.7 Quantitative real-time PCR – Cells were harvested at ~70% confluency and total RNA 
was isolated using the mirVANA miRNA isolation kit (Ambion/ Life Technologies, Grand 
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Island, NY). Final RNA isolates were checked for quality and concentration using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop/ThermoFisher Scientific). Specific 
primers for GRP78, CHOP, and HSPA1A (Applied Biosystems/Life Technologies) were 
amplified by Taqman-based one-step real-time PCR (Ambion/Life Technologies; ABI 
7900HT Fast Real-Time PCR System). 
2.1.8 Immunofluorescence - Cells were plated on either 4-well (50,000 cells/well) or 8-well 
(20,000 cells/well) chamber slides and allowed to attach overnight. Following drug 
exposure, cells were fixed and permeabilized with either acetone or 4% paraformaldehyde 
and 100µg/mL digitonin. Slides were blocked in 5% horse serum and 1% goat serum and 
then the primary antibody was added overnight. Fluorescent secondary antibodies, Cy3 or 
DyLight 549 anti-mouse (Jackson Immunoresearch Labs, West Grove, PA) were added for 1 
hour at room temperature. Nuclei were counterstained with a 1:10,000 dilution of Sytox 
Green and coverslips mounted using propyl gallate. Cells were imaged using a Zeiss 
Axioplan 2 fluorescent microscope mounted with a Hamamatsu ORCA-ER camera. 
2.1.9 Detergent-insoluble protein aggregates assay - Cells (50-70% confluency) were 
exposed to bortezomib for 24 hours and collected via scraping on ice. Cells were lysed by 
gentle rotation for 15 minutes at 4°C in the 1% Triton X-100 buffer described previously. 
Detergent-soluble and -insoluble fractions were isolated by centrifugation at maximum 
speed (16,000x g) for 15 minutes. The resulting supernatants were saved as the detergent-
soluble fraction, while the resulting pellets were resuspended in a 6M urea-containing 
sample buffer by sonication for 15 seconds and saved as the detergent-insoluble fractions. 
Proteins were resolved by 10% SDS-PAGE and membranes probed with an anti-ubiquitin 
antibody. Densitometry was performed using ImageJ. 
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2.1.10 Measurement of reactive oxygen species (ROS) – Cells (50-70% confluency) were 
plated in 6-well plates and allowed to attach overnight. Where indicated, 10 mM NAC was 
added 1 hour prior to bortezomib exposure. Cells were then exposed to bortezomib for 18 
hours. One hour prior to harvesting, 1µM of the redox-sensitive dye 2',7'-dichlorodihydro-
fluorescein diacetate (H2DCFDA) (Invitrogen/Life Technologies, Grand Island, NY) was 
added to each well. Cells were then collected by trypsinization and washed 1x in cold PBS. 
H2DCFDA fluorescence was measured on the FL1 channel of a Beckman Coulter FC500 
cytometer. Histograms overlays were generated using FlowJo software (Tree Star, Inc., 
Ashland, OR). 
2.1.11 siRNA-mediated gene silencing assays - Cells were transfected with ON-
TARGETplus SMARTpool siRNAs specific for GCN2, HRI, PERK,  or PKR, or a non-
targeting control (Dharmacon RNAi Technologies/Thermo Scientific). All targets were 
silenced via the reverse-transfection protocol included with the RNAiMAX transfection 
reagent (Invitrogen/ Life Technologies) for 72 hours before exposing cells to drug. Target-
specific knockdown was verified by quantitative RT-PCR. 
2.1.12 Statistics – Statistical analyses were performed using Student’s t test functions from 
GraphPad Prism 5 software and Microsoft Excel. P-values of < 0.05 were considered 
statistically significant. 
 
2.2 Materials and Methods for Chapter 4 
 
2.2.1 Cell lines and reagents:  Bladder cancer cell lines were obtained from the MD 
Anderson Bladder Cancer SPORE Cell Line Repository and maintained in MEM 
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supplemented with 10% fetal bovine serum (FBS) (Omega Scientific, Tarzana, CA).  The 
authenticity of all of the cell lines was confirmed at deposit by DNA fingerprinting, and 
their identities were routinely confirmed during experimentation in the MD Anderson 
Characterized Cell Line Core (97).  Bortezomib was purchased from ChemieTek (IN, USA). 
For in vitro experiments, bortezomib was dissolved in DMSO at a stock concentration of 10 
mM, sterilized by filtration through a 0.22 µm syringe filter, with aliquots stored at -20°C 
until use. Prior to use, the stock was diluted in medium to the desired concentrations. For 
injection of mice, bortezomib was dissolved in saline containing 10 mg/mL mannitol just 
before treatment. 
2.2.2 Cell viability assays:  Cells were exposed to bortezomib, collected at the indicated time 
points by trypsinization, and resuspended in 500 µl PBS. Fifty µl PBS, pH 7.4, containing 
100 µg/ml propidium iodide (PI) was added to the resuspended cells, and PI uptake 
(indicative of cell death) was analyzed immediately by flow cytometry (FACS) on a 
Cytomics FC 500 with CXP Software (Beckman Coulter, Inc., Fullerton, CA. For trypan 
blue exclusion, cells were collected by trypsinization, stained with 0.4% trypan blue 
(Invitrogen), and cells were counted using a hemocytometer. The experiment was conducted 
in triplicate. 
2.2.3 Microarray analyses:  Microarray experiments were performed as described previously 
(98) with minor modifications. RNA was isolated from cells using the TRIzol Reagent 
(Invitrogen), followed by cleanup with RNeasy Mini kits (Qiagen). RNA was used for the 
synthesis of biotin-labeled cRNA, which was prepared using the Illumina RNA 
amplification kit (Ambion, Inc.), and then hybridized to Illumina Human-HT12 (Illumina, 
Inc.) chips. Washed chips were scanned with BeadStation 500x (Illumina) and the signal 
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intensities quantified with BeadStudio (Illumina). The heatmap was made using Cluster 3.0 
and Java Treeview from Eisen lab (http://www.eisenlab.org/eisen/).  
2.2.4 mRNA extraction, reverse transcription and quantitative real-time PCR: mRNA 
extraction and reverse transcription were performed as described previously (99). RNA was 
isolated from cells using the TRIzol Reagent (Invitrogen), and cDNA synthesis was 
performed using SuperScript III First-Strand Synthesis System for RT–PCR (Invitrogen). 
Real-time PCR for HSPA1A, HSPA8, HSPB1, DNAJB1, and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was performed using a StepOne real-time PCR system (Applied 
Biosystems). The TaqMan primer sets for HSPA1A (Hs00359163_s1), HSPA1B 
(Hs00271244_s1), pan-HSPA1A & HSPA1B (Hs00271229_s1)HSPA8 (Hs03045200_g1), 
HSPB1 (Hs03044127_g1), DNAJB1 (Hs00428680_m1), and for GAPDH (4333764F) were 
purchased from Applied Biosystems. The amplification protocol consisted of one cycle at 
50°C for 2 min, one cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 
60°C for 60 s, and transcript levels were quantified using the comparative CT method. The 
resulting data were analyzed with StepOne software and expressed as the mean of ratios 
(relative expression to control) ± SE, and GAPDH served as the internal loading control. 
2.2.5 Treatment of cells with 5-aza-2’-deoxycytidine (5-AzdC): Cells were plated at low 
density (~5x104 cells/well) in 6-well plates and allowed to attach overnight. Cells were then 
exposed to 5µM 5-AzdC dissolved in 50% acetic acid for 5 days. Bortezomib (30nM) was 
then added to appropriate wells 6 hours prior to harvesting on day 5, and then cells were 
collected for RNA isolation. 
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2.2.6 DNA Methylation Analysis: Genomic DNA was isolated using a genomic DNA 
isolation kit (Qiagen). DNA (1 μg) was converted with sodium bisulfite using the EpiTect 
Bisulfite Kit (Qiagen) according to the manufacturer's instructions. The bisulfite-modified 
DNA was then subjected to methylation-specific PCR (MSP). The primers used for MSP 
were designed using Methprimer. The primer set for converted methylated DNA was 5’-
TGTTTTTTTTATTCGGATTAGTTAAC-3’ (forward) and 5’-
CCACCTACTCGCTAAAACTACGTA-3’ (reverse); The primer set for converted 
unmethylated DNA was 5’- TTTTTTTTATTTGGATTAGTTAATGT -3’ (forward) and 5’- 
CCCACCTACTCACTAAAACTACATA -3’ (reverse). The PCR protocol included an 
initial incubation at 95 °C for 10 min, followed by 35 cycles of 95 °C for 30 s, 49 °C for 30 s 
and 72 °C for 40 s, followed by one cycle of 72 °C for 10 min. MSP PCR products were 
separated on 2% agarose gels and visualized by ethidium bromide staining. Fully methylated 
control DNA and unmethylated control DNA were used as controls. 
 
2.2.7 Immunoblotting:  Cells were harvested by trypsinization and lysed in buffer containing 
20 mM Tris-HCl (pH 7.5),150 mM NaCl,1 mM Na2EDTA,1 mM EGTA, 1% Triton, 2.5 
mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml 
leupeptin and 1mM PMSF. Whole-cell extracts (20 µg total protein) were subjected to 
sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes were probed 
first with either a monoclonal antibody specific for the Hsp72 (SPA-810, Stressgen) or 
human beta-actin (Sigma, St. Louis, Mo.), and then with appropriate horseradish peroxidase-
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conjugated second antibodies (Santa Cruz). Immunodetection was performed using ECL 
(Amersham, Piscataway, N.J.) according to manufacturer’s instructions. 
 
2.2.8 Chromatin Immunoprecipitation:  Chromatin Immunoprecipitation (ChIP) was 
performed with the ChIP-IT™ Express Enzymatic kit, and ChIP-IT™ Control Kit (Active 
Motif) according to the manufacturer's protocol. Control and bortezomib-treated 253JB-V 
and UM-UC13 cells (1.5 x 107 each) were fixed for 8 minutes at room temperature and 
sheared by enzymatic digestion for 10 minutes. The sheared chromatin yielded bands 
between 200-1500 bp as visualized by agarose gel electrophoresis. DNA bound to HSF1 
was precipitated with an anti-HSF1 antibody (Stressgen, SPA901). To amplify the HSF1-
bound HSPA1A promoter, the precipitated DNA was subjected to real-time PCR using the 
TaqMan® Gene Expression Master Mix with Custom TaqMan® Gene Expression Assay 
primers (ABI) corresponding to the HSF-1-binding region of the HSPA1A promoter (-10 to 
-180) (100, 101). Real-time PCR was performed using ABI StepOne with following 
conditions: 5 minutes at 50°C; 10 minutes at 95°C; then 40 cycles of 95°C for 15 seconds, 
60°C for 60 seconds. The data presented represent results from three separate ChIP 
experiments and were normalized to reactions performed with 1% of input. End-point PCR 
reactions were also performed as described previously (37) to confirm the real-time PCR 
results. Normal IgG antibody was used as a control. 
 
2.2.9 Molecular modulation of HSPA1A gene expression:  The lentiviral pLKO.1-based 
constructs TRCN0000008762 and TRCN0000008757 specifically targeting the Hsp72 gene 
were purchased from Open Biosystems, Inc. The empty pLKO.1 vector was used as a 
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control. Recombinant viruses were produced by calcium phosphate transfection of 
HEK293T cells using standard protocols. At day 2–3 post-culture, 253J BV cells were 
incubated with shRNAs and polybrene (6 µg/ml) for 16~24 hours, and the transduced cells 
were selected in 1 µg/ml puromycin.  For overexpression of  HSP72, the Precision 
LentiORF RFP control (OHS5832) and Precision LentiORF individual clone for HSPA1A 
(OHS5897-100998480) were purchased from Open Biosystems, Inc. Transduced cells were 
selected in 5 µg/ml blasticidin and FACS sorting of GFP positive cells. 
2.2.10 Lysosomal integrity assays: Cells (~1-2x105) were plated in 6-well plates and allowed 
to attach overnight. Cells were then exposed to bortezomib for 24 h.  Following drug 
treatments, 100nM LysoTracker Red DND-99 (Molecular Probes/ Life Technologies, Grand 
Island, NY) was added to cells for 30 minutes prior to harvest. Cells were trypsinized, 
washed once with PBS, and resuspended in fresh PBS, and fluorescence was measured using 
a Beckman Coulter FC500 flow cytometer. 
2.2.11 Xenograft studies:  Nude mice (NIH, 6 weeks of age) were inoculated subcutaneously 
(s.c.) with 2X106 253J B-V cells transduced with the HSPA1A shRNA construct (253JB-
V.KDHsp72) or a non-targeting control construct (253JB-V.NT) (10 mice/group). When 
tumors became palpable (5~7 days), the mice were randomly assigned to control or 
treatment groups. The mice were treated i.v. (via the tail vein) biweekly with 1 mg/kg 
bortezomib formulated in saline containing 10 mg/mL mannitol in a volume of 100 µl or 
with 100 µl saline containing 10 mg/mL mannitol as a vehicle control. Caliper 
measurements of the longest perpendicular tumor diameters were performed twice a week 
after the start of treatment, and the volumes of tumors were calculated using the formula: 
W*W*L/2 (where W and L represented transverse diameter, and longest longitudinal). For 
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H&E analysis, tumors were collected from mice 24 hours after the second drug treatment 
and then fixed in OCT and 10% formalin.  
2.2.12 UCSC Genome Browser: The UCSC Genome Browser (102) was used to identify the 
presence of a CpG island surrounding the HSPA1A promoter region, Within the Genome 
Browser, the encyclopedia of DNA elements consortium (ENCODE) database (103) was 
used to identify the presence of methylation in other cell types. The UCSC Genome Browser 
is publically available at the following site: http://genome.ucsc.edu/ 
2.2.13 Statistics: Statistics were performed as described previously in 2.1.12 
 
2.3 Materials and Methods for Chapter 5 
2.3.1 Cell lines, culture, and chemicals – Human pancreatic cancer cells and bladder cancer 
cells were obtained and grown as described above (Chps. 3 and 4 Materials and Methods, 
respectively). Cell line identities were confirmed using DNA fingerprinting analysis in the 
MD Anderson Characterized Cell Line Core. Multiple myeloma cells MM1, U266, RPMI-
8226, and OPM-2 cells were obtained from Robert Orlowski at MD Anderson and grown in 
suspension in RPMI media supplemented with L-glutamine. Bortezomib and propidium 
iodide were obtained as described in Chp. 2.1. 
2.3.2 Antibodies and immunoblotting –Antibodies were purchased from the following 
sources: HDAC6 (Santa Cruz Biotechnology, Santa Cruz, CA), HDAC1, total α-tubulin, 
acetylated α-tubulin, histone H3, and acetylated histone H3 (Cell Signaling Technology, 
Beverly, MA). Anti-mouse and anti-rabbit HRP-conjugated secondary antibodies were 
obtained from Promega, Madison, WI. Immunoblotting was done as described in Chp. 2.1.  
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2.3.3 Measurement of cell viability – Propidium iodide-uptake assays (measuring outer 
membrane integrity and total cell death) were performed as described in Chp 2.1. DNA 
fragmentation was analyzed on the same samples; following collection and measurement of 
membrane integrity, cells were washed and resuspended in 500µL DNA fragmentation 
buffer (50µg/mL propidium iodide in PBS + sodium citrate). Cells were incubated in the 
dark at 4˚C for at least 1 hour prior to FACS analysis on the FL3 channel of a Beckman 
Coulter FC500 cytometer. Sub G0-G1 cells were gated and quantified as the percentage of 
cells with fragmented DNA (subdiploid). 
2.3.4 MTT assays –L3.6pl pancreatic cancer cells (5×103) were plated in 96-well plates and 
allowed to attach overnight before exposing them to the indicated concentrations of 
bortezomib, Compound A, SNDX-275, or SAHA inhibitors for 48 hours. Conversion of 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to formazan salt was 
used to measure relative numbers of viable cells in each well. Following drug exposure, 50 
µL of MTT solution (50μg/ml in PBS) was added to each well and cells were incubated for 
2 more hours. Next, medium was aspirated and replaced with DMSO (100 µL). A 
colorimetric assay using a standard micro-plate reader was used to determine the amount of 
MTT in each well via absorbance at 600 nm.  
2.3.5 siRNA-mediated transient silencing assays – HDAC1, 2, 3, and 6 siRNAs 
ONTARGETplus SMARTpool siRNAs as well as a non-targeting control siRNA were 
purchased from Dharmacon/Thermo Scientific. Genes were silenced for 48-72 hours as 
described in Chp. 2.1 prior to drug exposure. Knockdown efficiencies were verified by qRT-
PCR with primers specific for each target (Applied Biosystems/ Life Technologies).  
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2.3.6 shRNA-mediated stable gene knockdown assays – Cells were plated at ~30-40% 
confluency and allowed to attach overnight. pGIPZ plasmids containing hairpin sequences 
directed against HDAC6 or HDAC1 and a puromycin resistance gene(Open Biosystems) 
were packaged in lentiviral vectors and delivered to cells with polybrene in antibiotic-free 
medium (5µg/mL). After a 24h incubation with lentivirus, medium was replaced and cells 
grew to confluency. After several days, cells were selected and maintained with puromycin 
(5-10µg/mL) and knockdown levels were confirmed at the RNA and protein level. 
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Chapter 3. LACK OF INDUCIBLE eIF2A 
PHOSPHORYLATION IS ASSOCIATED WITH 
SENSITIVITY TO BORTEZOMIB IN PANCREATIC 
CANCER CELLS 
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3.1 Introduction 
 As detailed in Chapter 1 (Section 1.3.2b), eIF2α phosphorylation effectively shuts 
off global protein synthesis in response to stress, and also selectively upregulates the ATF4-
mediated ISR. This phosphorylation is thought to be controlled by one of the four known 
stress-activated kinases, HRI, GCN2, PKR, and PERK, each activated by distinct stresses 
(see Fig. 1.5). Our group became interested in eIF2α through our work on the mechanisms 
underlying the cytotoxicity of proteasome inhibitors (PIs) in solid tumor models (71, 88, 
104, 105). This work led to discovery of heterogeneity in PI-induced cytotoxicity among 
panels of cell lines both within and across tissue types. In addition, we noticed that only 
certain subsets of cancer cells appeared to phosphorylate eIF2α upon stress, and only certain 
subsets of our cancer cell lines formed large centralized aggregates known as aggresomes 
following PI exposure, indicating differences in protein aggregation levels (104). Perhaps 
the most convincing hypothesis for PI-induced cell death revolves around a proteotoxicity-
based mechanism of action (see Section 1.3.3b); specifically, our view was that 
accumulation of aggregated proteins following proteasome inhibition precipitated cell death. 
The results of our work and others’ led to the hypothesis that perhaps eIF2α phosphorylation 
is the central mechanism controlling proteostasis upon proteasome inhibition, and that cells 
that failed to phosphorylate eIF2α and shut off protein synthesis would be susceptible to 
enhanced protein misfolding/aggregation and thus be more sensitive to PIs.  
 Pancreatic cancer is an attractive disease site to study proteotoxic stress for several 
reasons. The pancreas is a secretory organ, containing small populations of islet (isle of 
Langerhaan’s) cells responsible for secreting insulin and glucagon, while the majority of the 
organ is composed of acinar cells that secrete digestive enzymes into the intestine. PERK, as 
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previously described, is the only known ER-membrane resident eIF2α kinase known, and 
phosphorylates eIF2α in response to misfolded proteins and ER stress (106). Studies from 
PERK -/- mice (52) provided strong evidence that PERK-eIF2α signaling is particularly 
important to the pancreas. Zhang, et al. showed that, contrary to most other tissues, the wild-
type pancreas has high levels of phosphorylated-eIF2α. This phosphorylation was shown to 
be controlled by glucose availability: when the mice were injected with glucose after fasting, 
phosphorylation levels dropped fivefold, while serum insulin levels rose dramatically. 
Correspondingly, expression of PERK was also high in the wild-type pancreas. Expectedly, 
Perk-/- mice showed a loss of islet cells leading to decreased insulin and diabetes early in the 
postnatal growth period, and also showed a decrease in secretion of digestive enzymes, 
leading to digestive problems. It is unclear as to which of the three pancreatic cell types, 
ductal, acinar, or islet, is the cell of origin for pancreatic cancer (107, 108). In culture, our 
pancreatic cancer cell models do not retain the secretory protein expression profile seen in 
acinar cells, possibly because they originated from non-secretory pancreatic ductal cells, or 
perhaps because of changes as a result of malignant transformation or even the cell culture 
process (109). Importantly, when compared with their malignant counterparts, normal 
pancreatic cells possess lower overall translation rates and a better ability to attenuate 
translation in response to stress (88), (Jennifer Choe, unpublished results).  
 Therefore, we sought to understand the relationship between eIF2α phosphorylation 
and BZ sensitivity among a panel of 10 distinct pancreatic cancer cell lines derived from 
human tumors. Through the course of this study we also sought to characterize the nature of 
intracellular stress caused by proteasome inhibition.  Our work and others’ (88, 105, 110) 
has suggested that PI’s induce significant ER stress; however, the cytosolic heat shock 
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response is also known to be strongly activated by PIs as well (32, 33). By examining the 
etiology of PI-induced stress, we hoped to gain a better understanding of the downstream 
stress response and identify new, rationale targets that may be inhibited to overcome BZ 
resistance. Activation of autophagy is also thought to be a significant compensatory 
response to PIs that lies downstream of the initial stress response (71). Another major goal 
of our study was to identify the specific eIF2α kinase (either HRI, GCN2, PKR, or PERK) 
that is activated by BZ.  If eIF2α phosphorylation is indeed cytoprotective, it follows that 
blocking phosphorylation by targeting the BZ-activated eIF2α kinase would sensitize cells 
to BZ.  
 Here, we show that BZ sensitivity correlates with a lack of inducible eIF2α 
phosphorylation among a panel of human pancreatic cancer cell lines. The sensitive cells 
failed to sufficiently arrest translation, and this led to extensive protein aggregation that was 
associated with oxidative stress and ultimately, cell death. BZ appeared to more strongly 
induce expression of cytosolic stress response chaperones (Hsp72) than ER stress 
chaperones (Grp78/BiP) and transcription factors (CHOP/GADD153). Accordingly, we 
identify the cytosolic eIF2α kinase HRI as most strongly activated by BZ, and demonstrate 
that knockdown of HRI can reverse resistance to BZ. Overall, this work provides important 
clarification regarding how molecular heterogeneity of the eIF2α stress response pathway 
influences BZ-induced cytotoxicity in pancreatic cancer cells, and identifies new targets for 
therapy (HRI) within this pathway. 
 
 
44 
 
3.2 Results  
3.2.1 Heterogeneous effects of bortezomib on cell death and eIF2α phosphorylation in 
pancreatic cancer cells - We previously observed significant heterogeneity among human 
pancreatic cancer cell lines in the levels of apoptosis induced by proteasome inhibitors 
(104). Here we examined a new panel of cells to determine their sensitivities to a clinically 
relevant concentration of bortezomib (BZ) using a plasma membrane integrity assay (PI-
uptake) that measures cumulative cell death. Immortalized normal pancreatic ductal 
epithelium cells (HPDE) were used as a control and were relatively resistant to BZ, as was 
reported previously using DNA fragmentation assays (104). Among the cancer cells we 
observed a wide range of responses indicative of inter-tumoral heterogeneity in drug 
sensitivities (Fig. 3.1). We performed time course experiments to measure eIF2α 
phosphorylation in two drug-sensitive (CF-Pac1, T3M4) and two drug–resistant (mPanc96, 
Suit2) cell lines. Neither BZ nor the ER stress-inducing agent thapsigargin (TG) induced 
eIF2α phosphorylation in the sensitive cell lines, whereas both compounds promoted strong 
induction in the resistant lines (Fig. 3.2). We then compared the effects of BZ and TG on 
eIF2α phosphorylation in the rest of the cell lines in the panel.  Overall, there was an 
excellent correlation between lack of eIF2α phosphorylation and BZ sensitivity (Fig. 3.2-
3.3). Only two of the cell lines that exhibited intermediate drug sensitivities (L3.6pl and 
Panc1) did not conform to this pattern (Fig. 3.3).  
3.2.2 Effects of bortezomib on translation and protein aggregation - We 
hypothesized that lack of inducible eIF2α phosphorylation might prevent efficient 
translational attenuation leading to toxic accumulation of misfolded protein 
aggregates. To test this hypothesis, we utilized a L-[4,5- 3H(N)] leucine incorporation 
assay to measure rates of protein synthesis inA 
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Figure 3.1. Heterogeneous sensitivities of pancreatic cancer cell lines to bortezomib. 10 
distinct human pancreatic cancer cell lines and one normal immortalized pancreatic ductal 
epithelial cell line (HPDE) were exposed to 10 and 30 nM concentrations of bortezomib 
(BZ) for 48 hours. A) Viability was measured by outer membrane integrity using PI-
uptake/FACS analysis (A). B) Apoptosis was determined by PI-based cell cycle analysis of 
sub G0-G1 cells. Columns represent mean + SE (n=3).  
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Figure 3.2. Bortezomib sensitivity correlates with lack of inducible eIF2α 
phosphorylation in human pancreatic cancer cells. Time-course of eIF2α 
phosphorylation. BZ-resistant (Suit2, mPanc96) and BZ-sensitive (T3M4, CF-Pac1) were 
exposed to 10µM thapsigargin (TG) or 10nM BZ (BZ) for the indicated times and the levels 
of phosphorylated and total eIF2α were measured by immunoblotting, with β-actin serving 
as a loading control. Data are representative of n=3. 
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Figure 3.3. Characterization of eIF2α phosphorylation in additional cell lines. Cells 
were exposed to 10nM BZ for 6 hours (BZ) or 10µM thapsigargin for 2 hours (TG) and 
eIF2α phosphorylation was measured by immunoblotting. Data are representative of 
duplicate experiments. 
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cells exposed to BZ. The results (Fig. 3.4) confirmed that translation attenuation was 
delayed in the BZ-sensitive cell lines, which continued incorporating leucine into protein at 
> 100% of control levels for up to 8 hours after BZ exposure, whereas the resistant cells 
down-regulated translation much earlier (2-4 hours). The results were not related to 
differences in the basal protein synthesis rates among sensitive and resistant cells (Fig. 
3.5A). Sensitivity of the assay was also validated using the translation inhibitor 
cycloheximide (CHX), which caused similar levels of translational inhibition in all of the 
cell lines (Fig. 3.5B). 
Based on the protein synthesis data, we suspected that the BZ-sensitive cell lines 
would accumulate protein aggregates more readily than the resistant cells. We examined the 
time-dependent effects of BZ on the accumulation of ubiquitin-positive aggregates in the 
sensitive CF-Pac1 and T3M4 cells using anti-ubiquitin immunofluorescence microscopy, 
and the results revealed that visible aggregates began to form at 12 hours (Fig. 3.6). We then 
used the same assay to measure protein aggregation in the resistant cells at this time point. 
Strikingly, immunofluorescence analyses revealed almost no ubiquitin-positive aggregates 
in either of the BZ-resistant cells (mPanc96 or Suit2) (Fig. 3.7). To confirm these results 
with a different method, we used a variation of a detergent-insoluble protein aggregation 
assay reported previously (111). Again, BZ induced higher levels of ubiquitin-positive 
aggregates in the insoluble fractions of CF-Pac1 and T3M4 than in mPanc96 or Suit2 cells 
(Fig. 3.8). To explore whether a causal link existed between protein aggregation and cell 
death, we pre-incubated BZ-sensitive cells with CHX prior to exposing them to BZ and 
examined the effects on BZ-induced protein aggregation and cell death (Fig. 3.9). 
Immunofluorescence confirmed that CHX prevented BZ-induced protein aggregation in CF- 
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Figure 3.4. Bortezomib-sensitive cells display impaired translation attenuation. 
Measurement of bortezomib (BZ)-induced translational arrest. Left panel, BZ-resistant 
(Suit2, mPanc96) and BZ-sensitive (CF-Pac1, T3M4) cells were exposed to 30nM 
bortezomib for the indicated times, and protein synthesis was measured by L-[4,5- 3H(N)] 
leucine incorporation. Points represent mean + SE (n=4). *Represents time point at which 
values became significantly different from untreated controls (P < 0.05). 
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Figure 3.5. Differences in translation attenuation are not due to inherent differences in 
protein synthesis rates between cell lines or to L-[4,5- 3H(N)] leucine incorporation 
assay sensitivity.  A) Basal levels of protein synthesis among sensitive (CF-Pac1, T3M4) 
and resistant (mPanc96, Suit2) cells, normalized to CPMs per µg of protein loaded. B)  
Sensitivity of L-[4,5- 3H(N)] leucine incorporation assay validated by cycloheximide, a 
positive control for inhibition of translation. Columns represent mean + SE (n=3). 
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Figure 3.6. Bortezomib-sensitive cells form ubiquitin-positive protein aggregates 
following exposure to bortezomib. Measurement of ubiquitin-positive aggregates by 
immunofluorescent staining. CF-Pac1 and T3M4 were exposed to 10nM BZ for indicated 
times. Blue = nuclear stain; green = ubiquitin. Magnification = 20x. Images are 
representative of 2 independent experiments.. 
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Figure 3.7. Bortezomib induces different levels of visible ubiquitin-positive aggregates 
in sensitive and resistant cells. A, ubiquitin immunofluorescent staining. mPanc96, Suit2, 
CF-Pac1, and T3M4 were plated in chamber slides and exposed to 10nM BZ for 12h. After 
fixation, cells were stained for ubiquitin (green) and nuclei (blue). Magnification = 20x. 
Images are representative of 2 independent experiments. 
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Figure 3.8. Bortezomib-sensitive cells have higher levels of ubiquitin in detergent-
insoluble fraction after bortezomib exposure. T3M4, CF-Pac1, mPanc96, and Suit2 cells 
were exposed to 10nM bortezomib (BZ) for 24h, detergent insoluble fractions were isolated, 
and ubiquitin-positive aggregates were detected by immunoblotting. Lamin A/C served as a 
loading control. The numbers located below each lane correspond to levels of ubiquitin, as 
determined by densitometry and adjusted to lamin A/C levels. Results are representative of 3 
independent experiments. 
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Figure 3.9. Chemical inhibition of translation prevents bortezomib-induced protein 
aggregation and cell death. A, ubiquitin immunofluorescence. CF-Pac1 cells with and 
without a 2 hour preincubation with 20µM cycloheximide (CHX) were exposed to 30nM 
bortezomib (BZ) for 24 hours, then fixed and stained. Green represents ubiquitin, blue 
represents the nuclear stain. Magnification = 20x. Right panel, >100 cells from at least 2 
representative images from 2 independent experiments were scored for the presence/absence 
of at least one ubiquitin-positive aggregate. Columns represent mean + SE. (n=2). B, effects 
of cycloheximide (CHX) on bortezomib-induced cell death. T3M4 and CF-Pac1 cells with 
and without a 2 hour preincubation with 20µM CHX were exposed for 48 hours to 30nM BZ 
as indicated. Cell viability was determined by PI-uptake/FACS analysis. Columns represent 
mean + SE (n=3). *P <0.01 compared with BZ alone. 
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Pac1 cells (Fig. 3.9A,B).  The inhibitor also prevented BZ-induced death in the CF-Pac1 and 
T3M4 cells (Fig. 3.9C). 
3.2.3 Bortezomib-induced oxidative stress mediates cell death – Protein misfolding and 
aggregation have been implicated in the production of ROS (112-115). It therefore seemed 
possible that ROS production might underlie the protein aggregate-associated toxicity of BZ 
in pancreatic cancer cells. To test this, we measured intracellular BZ-induced peroxide 
production with 2',7'-dichlorodihydro-fluorescein diacetate (H2DCFDA). Following 
exposure to BZ for 18h (a time point which follows initial aggregate formation but precedes 
cell death), the sensitive cell lines BxPC3, CF-Pac1, and T3M4 displayed significant 
rightward shifts in H2DCFDA fluorescence, indicating increased production of ROS, 
whereas the resistant cell lines mPanc96, Suit2, and MiaPaCa-2 did not (Fig. 3.10). 
Furthermore, the thiol antioxidant N-acetyl-L-cysteine (NAC) prevented both BZ-induced 
ROS production and cell death (Figs. 3.11, 3.12).  
3.2.4 Bortezomib induces Hsp72 mRNA levels but not Grp78/BiP or CHOP/GADD153 – To 
better understand the BZ-induced stress response, we measured biomarkers associated with 
either cytosolic or ER stress responses. BZ induced similar levels of ER stress (as measured 
by Grp78/BiP levels) in both sensitive and resistant cell lines (Fig. 3.13A). In addition, 
levels of CHOP/GADD15, were also similar following BZ exposure (Fig. 3.13B). 
Strikingly, when compared with a classic ER stressor such as TG, BZ was a relatively weak 
inducer of both Grp78 and CHOP, but it was a much more potent inducer of the cytosolic 
and heat shock-inducible homolog of Grp78, Hsp72 (Fig. 3.13C). In addition, TG did not 
induce significant cytotoxicity in any of the cell lines (Fig. 3.14).  Previous work implicated 
CHOP in proteasome inhibitor-induced cell death (5). We therefore also examined the  
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Figure 3.10. Bortezomib induces reactive oxygen species (ROS) in sensitive cells. ROS 
levels in resistant (mPanc96, Suit2, MiaPaCa-2) and sensitive (BxPC3, CF-Pac1, T3M4) 
cells measured by H2DCFDA fluorescence (FL1 channel) after an 18 h exposure to 30nM 
BZ. Data are representative of three independent experiments. 
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Figure 3.11. Antioxidants block bortezomib-induced ROS production. Pre-treatment 
with 10mM of the antioxidant N-acetyl-L-cysteine (NAC) blocks ROS production following 
an 18 hour exposure to 30nM BZ in two sensitive cell lines, BxPC3 and CF-Pac1. Data are 
representative of three independent experiments.  
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Figure 3.12. The antioxidant N-acetyl-L-cysteine (NAC) prevents bortezomib-induced 
cell death. CF-Pac1 and BxPC3 cells were pre-exposed to 10mM NAC for 1 hour prior to a 
48 hour BZ exposure. Cell death was measured by PI-uptake/FACS analysis. Columns 
represent mean of dead cells + SE. *P < 0.02 compared to BZ column. 
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Figure 3.13. Effects of bortezomib on biomarkers of ER and cytosolic stress. A, effects 
on the ER stress marker Grp78/BiP; B, effects on the ER stress marker CHOP/GADD153; 
C, effects on the cytosolic stress marker Hsp72. mPanc96, Suit2, CF-Pac1, and T3M4 cells 
were exposed to 10µM thapsigargin (TG) or 10nM bortezomib (BZ) as indicated. 
Expression levels were determined by one-step quantitative RT-PCR. RQ, relative quantity 
as normalized to the internal control (cyclophilin A). Columns represent mean + SE (n=3). 
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Figure 3.14. Dichotomy between bortezomib-sensitive and -resistant cells does not exist 
when exposed to the ER stress-inducing agent thapsigargin. Thapsigargin (TG)-induced 
ER stress does not induce significant cell death. mPanc96, Suit2, CF-Pac1, and T3M4 cells 
were exposed to TG for 48 hours at the concentrations indicated. Cell death was measured 
by PI-uptake/FACS analysis. Columns represent mean + SE (n=3). 
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effects of CHOP knockdown on BZ-induced cell death in the Suit2 and CF-Pac1 cells.  In 
contrast with the previous work, CHOP knockdown actually promoted cell death (Fig. 3.15).  
Therefore, the nature of the proteotoxic stress caused by BZ appears to be more similar to 
heat shock than to ER stress, and is primarily cytosolic in origin. 
3.2.5 Identification of BZ-activated eIF2α kinase(s) – Given that BZ induced primarily 
cytosolic stress, it seemed likely that an eIF2α kinase other than PERK might be primarily 
responsible for the BZ-induced eIF2α phosphorylation observed in the resistant cells. We 
therefore examined the concentration-dependent effects of BZ on activation of the eIF2α 
kinases HRI, PERK, and GCN2 by immunoblotting.  As positive controls we used amino 
acid starvation (leucine deprivation) and TG to induce activation of GCN2 and PERK, 
respectively. We monitored GCN2 activation using a phospho-specific antibody, and we 
measured HRI and PERK activation indirectly by monitoring the appearance of slower 
migrating species of the kinases by SDS-PAGE and immunoblotting because reliable 
commercial phospho-specific antibodies were not available. Bortezomib caused dramatic 
HRI mobility shifts in the Suit2 and CF-Pac1 cells, whereas its effects on PERK were much 
more modest, especially when compared to the effects of TG (Fig. 3.16). Neither BZ nor TG 
had any detectable effect on GCN2 phosphorylation (Fig. 3.16).  Importantly, BZ induced 
similar effects on HRI and PERK in the drug-sensitive and –resistant cells, indicating that 
the lack of increased eIF2α phosphorylation in the sensitive cells was not caused by 
defective kinase activation. Basal levels of HRI and GCN2 were slightly higher in BZ-
sensitive versus –resistant lines but none of the kinases were upregulated by BZ (Fig. 3.17). 
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Figure 3.15. CHOP knockdown promotes cell death and sensitizes cells to bortezomib. 
(A) Suit2 and (B) CF-Pac1 cells were transfected with siRNA specific for CHOP (siCHOP)  
as well as a non-targeting control siRNA (NT). Cells were then exposed to indicated 
concentrations of BZ for 48h, and cumulative cell death measured by PI-uptake/FACS 
analysis. Left panels, columns represent mean cell death + SE (n=2). Right panels, 
knockdown efficiencies for CHOP determined by one-step quantitative RT-PCR. RQ, 
relative quantity as normalized to the internal control (cyclophilin A). Columns represent 
mean + SE (n=2). 
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Figure 3.16. Identification of bortezomib-activated eIF2α kinase(s). Analysis of HRI, 
PERK, and GCN2 activation following bortezomib exposure. Suit2 and CF-Pac1 cells were 
either exposed to indicated concentrations of bortezomib (BZ) for 6 hours, leucine-starved 
for 2 hours, or exposed to 10 µM thapsigargin (TG) for 2 hours. Phosphorylated and total 
kinase levels were measured by immunoblotting. Data are representative of three 
independent experiments. 
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Figure 3.17. eIF2α kinase expression among bortezomib-sensitive and-resistant cells. 
Suit2, mPanc96, T3M4, and CF-Pac1 cells were left untreated or exposed to 10nM BZ for 
6h (BZ), and HRI, GCN2, PKR, and PERK mRNA levels were measured by one-step 
quantitative RT-PCR. Columns represent mean + SE (n=2). 
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3.2.6 GCN2 controls constitutive phosphorylation of eIF2α– We noticed that most of the 
BZ-sensitive cell lines had elevated levels of phospho-eIF2α at baseline (Fig. 3.2). We 
confirmed this by immunoblotting (Fig. 3.18A, left panel), and the differences between 
sensitive (CF-Pac1, T3M4) and resistant (mPanc96, Suit2) cells were significant (Fig. 
3.18A, right panel). To identify the responsible kinase, we used RNAi to knock down 
expression of HRI, GCN2, and PERK in the CF-Pac1 cells and examined phospho- and 
total-eIF2α levels by immunoblotting (Fig. 3.18B, left panel) and confirmed knockdown 
efficiencies by RT-PCR (Fig. 3.19). The results revealed that GCN2 knockdown resulted in 
a significant reduction in basal phospho-eIF2α levels, whereas knockdown of the other 
kinases or transfection with a non-targeting control had no effect (Fig.3.18B, right panel).  
3.2.7 Inhibition of inducible eIF2α phosphorylation sensitizes cells to bortezomib – To more 
directly determine the contribution of eIF2α phosphorylation to cell death, we compared the 
effects of BZ in MEFs expressing either wild-type (51SS) or knock-in mutant (51AA) forms 
of eIF2α. The mutant 51AA cells were significantly more sensitive to BZ than the wild-type 
51SS cells (Fig. 3.20). We next tested whether knockdown of eIF2α kinases would sensitize 
cells to BZ (Fig. 3.21-22). Based on the kinase activation data (Fig. 3.16), we expected that 
knockdown of HRI, and to a lesser extent PERK, would promote cell death. Consistent with 
our expectations, HRI knockdown strongly promoted BZ-induced cell death in two resistant 
cell lines (Suit2, MiaPaCa-2). PERK knockdown produced some sensitization but less than 
HRI knockdown. GCN2 and PKR knockdown also modestly increased cell death over the 
non-targeting control, but the differences were not statistically significant (Fig. 3.21). 
Overall, the results demonstrate that HRI-mediated eIF2α phosphorylation antagonizes BZ-
induced cell death. 
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Figure 3.18. GCN2 controls constitutive eIF2α phosphorylation bortezomib-sensitive 
cells. A), Basal phospho-eIF2α levels in BZ-sensitive and BZ-resistant cells. Left panel, 
untreated lysates were analyzed for phospho- and total eIF2α levels by immunoblotting. 
Right panel, quantification of phospho- eIF2α levels by densitometry. Columns represent 
mean + SE (n=6).*P < 0.001, compared with CF-Pac1 and T3M4. B) Effects of silencing 
eIF2α kinases on basal phospho- eIF2α levels. CF-Pac1 cells were transfected with siRNAs 
specific for HRI, GCN2, or PERK, or a non-targeting control siRNA (NT). Right panel, 
columns represent the mean + SE (n=3). P < 0.05 compared to NT. 
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Figure 3.19. Knockdown efficiencies for eIF2α kinase siRNAs in CF-Pac1. A, CF-Pac1 
cells were transfected with siRNA specific for HRI, GCN2, or PERK for 72h, and kinase 
expression levels were measured by one-step quantitive RT-PCR. Columns represent mean 
+ SE (n=3).  
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Figure 3.20. Genetic ablation of eIF2α phosphorylation sensitizes cells to bortezomib. 
Effects of BZ on cell death in wild-type (51SS) and phosphorylation-deficient mutant 
(51AA) MEFs. Cells were exposed to 10nM bortezomib (BZ) for 72 hours, and cell viability 
was measured by PI-uptake/FACS analysis. Columns represent mean + SE (n=3).*P < 0.05 
compared to wild-type 51SS BZ-treated values. 
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Figure 3.21. HRI knockdown sensitizes cells to bortezomib. siRNA screen examining the 
effects of eIF2α kinase knockdown on bortezomib sensitivity. Suit2 and MiaPaCa-2 cells 
were transfected with siRNAs specific for HRI, GCN2, PKR, or PERK, as well as a non-
targeting (NT) control siRNA for 72 hours. The cells were then exposed to 30nM 
bortezomib (BZ) for 48 hours, and cell viability was measured by PI-uptake/FACS analysis. 
Columns represent mean + SE (n=3).*P < 0.05 compared to NT BZ-treated values.  
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Figure 3.22. Knockdown efficiencies for eIF2α kinase siRNAs in Suit2. Suit2 cells were 
transfected with siRNA specific for HRI, GCN2, PKR, or PERK for 72h, and kinase 
expression levels were measured by one-step quantitive RT-PCR. Columns represent mean 
+ SE (n=3). 
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3.2.8 LC3 punctae correlate with phospho-eIF2α levels – Activation of autophagy has been 
shown to be a crucial compensatory mechanism in response to proteasome inhibition (116). 
We previously demonstrated a coupling between eIF2α phosphorylation and autophagy 
induction following exposure to proteasome inhibitors (71); this coupling has also been 
observed in cells exposed to other stress stimuli (117, 118). It therefore seemed likely to us 
that the heterogeneity in eIF2α phosphorylation among our cell lines might also contribute 
to heterogeneous levels of both basal and drug-induced autophagy. To test this, endogenous 
microtubule-associated protein light chain 3 (LC3) punctae were measured by 
immunofluorescence in representative bortezomib-sensitive and -resistant cells. LC3 is 
conjugated to phosphatidylethanolamine (PE) and incorporated into autophagosomal 
membranes upon autophagy induction, and visualization of LC3 punctae is a reliable method 
for measuring formation of autophagosomes and autophagy induction (119, 120). Our data 
revealed both higher levels of basal autophagy in bortezomib-sensitive T3M4 and CF-Pac1 
cells (Fig. 3.23A), and also a less significant increase in bortezomib-induced LC3 punctae 
formation in these cells when compared with the bortezomib-resistant cell lines (Fig. 3.23B). 
This is consistent with the pattern of eIF2α phosphorylation seen in our cells, and suggests 
that inefficient induction of autophagy is another consequence of the impaired eIF2α 
response that contributes to bortezomib sensitivity in pancreatic cancer cells. 
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Figure 3.23. High basal eIF2α-P correlates with constitutively high levels of autophagy. 
A). Basal LC3 immunofluorescence. T3M4, CF-Pac1, Suit2, and mPanc96 cells plated on 
chamber slides and then probed for LC3 punctae formation. B) BZ-induced LC3 punctae 
formation. T3M4 and Suit2 cells were exposed to 10nM BZ for 18h prior to staining. Green 
represents LC3, blue represents nuclear stain. Images are representative of multiple images 
taken from at least 3 independent experiments. 
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3.3 Discussion 
 By attenuating translation and preventing the accumulation of misfolded and 
aggregated proteins, eIF2α phosphorylation serves to protect cells from proteotoxic stress. 
Our results show a clear relationship between lack of inducible eIF2α phosphorylation and 
BZ sensitivity. In highlighting the importance of translational control following proteasome 
inhibition, our data support the results of a recent study from Millenium Pharmaceuticals in 
which knockdown of other translation initiation factors (EIF4E, EIF4G1) prevented BZ-
induced death (121). Similarly, high levels of protein synthesis are known to sensitize 
multiple myeloma cells to PI’s (85).  A critical role for eIF2α phosphorylation in resistance 
to PI’s is also supported in MM, where resistant cells phosphorylate and then de-
phosphorylate eIF2α in response to PI’s, but inhibition of this de-phosphorylation was 
shown to be sufficient to reverse resistance (122). Others have suggested a pro-apoptotic 
role for eIF2α phosphorylation following proteasome inhibition (with MG-132) (58), which 
is contrary to our conclusions. Thus, although induced phosphorylation of eIF2α that 
remains at high levels and is not attenuated may lead to cell death, our model suggests that 
transient, inducible, phosphorylation protects cells (see Fig. 3.23), whereas constitutive, un-
inducible phosphorylation sensitizes cells to PI’s. We discovered that the GCN2 kinase 
controls this constitutive phosphorylation, but it is presently unclear as to why GCN2 would 
be activated at baseline in our BZ-sensitive cell lines. It is possible that this is an indication 
of an underlying metabolic stress resulting from a specific malignant phenotype. 
Interestingly, GCN2 mRNA expression was 2-3 fold higher in our BZ-sensitive cells (Fig. 
3.16). It is unclear as to why the BZ-sensitive cells are unable to modulate levels of 
phospho- eIF2α in response to stress (both BZ and TG). This could simply be a result 
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Figure 3.24. Proposed schematic of eIF2α phosphorylation profiles upon proteotoxic 
stress. Based on data from our study and others, we suggest 3 distinct forms of eIF2α 
phosphorylation with different downstream consequences: 1) Inducible, temporary 
phosphorylation = resolution of stress and cytoprotection; 2) Inducible, prolonged 
phosphorylation = terminal UPR and cytotoxicity (Schewe, et al. 2009); 3) Constitutive, un-
inducible phosphorylation = continued protein synthesis and buildup of aggregates, 
cytotoxicity. 
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of these cells already having maximal (saturated) phosphorylation, or perhaps be related to a 
more complex mechanism involving differential regulation of a specific phosphatase 
(potentially GADD34). Data from lung cancer links high phospo- eIF2α levels to better 
overall survival (123), and our data suggest that the possibility of constitutive eIF2α 
phosphorylation as a biomarker for BZ sensitivity should be further explored. In addition, 
the observation that levels of autophagy vary among our cell lines is particularly relevant in 
light of a recent study implicating high levels of basal autophagy in pancreatic cancer cells 
as essential for tumor growth (124).  Our study extends these observations by demonstrating 
that heterogeneity in autophagy levels exists among pancreatic cancer cells that is associated 
with basal eIF2α phosphorylation. Given that this basal phosphorylation is controlled by the 
amino acid- and nutrient-sensitive kinase GCN2, it seems likely that the high phospho-eIF2α 
levels are a symptom of some basal nutrient stress that is driving constitutive autophagy and 
potentially contributing to bortezomib sensitivity. 
 We propose that the mechanism behind the toxicity of the aggregates in the BZ-
sensitive cell lines is ROS production. Oxidative stress is known to be associated with 
misfolded protein accumulation in both neurodegenerative (112, 113), as well as non-disease 
causing proteins (114). Proteasome inhibitors have also been shown to induce ROS (125-
127), and recent clinical data in mantle cell lymphoma shows an association between higher 
ROS levels and improved outcomes following BZ treatment (128). The exact mechanism for 
how misfolded and aggregated proteins stimulate ROS production is presently unclear, 
although one possibility is through damaging interactions with cellular phospholipid 
membranes. Misfolding often exposes buried hydrophobic residues on the surface of 
proteins, resulting in either an amphipathic or net positive charge. Through electrostatic and 
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hydrophobic interactions, these toxic species can interact with and destabilize lipid 
membranes, potentially disrupting membrane receptors and ion pumps. Through this 
mechanism, ROS (superoxide) could leak through a destabilized outer mitochondrial 
membrane directly from the intermembrane space, or this could be stimulated by influx of 
Ca2+ ions (129).  Increases in intracellular Ca2+ levels correlate with exposure to aggregate-
prone proteins (130), and we have previously shown that increased Ca2+ levels are also 
associated with proteasome inhibition (88).   Our present data strengthen the link between 
protein aggregation and ROS, and even though our data do not identify the exact 
mechanism(s) by which protein aggregates stimulate ROS production, oxidative stress is an 
attractive explanation for the toxicity of protein aggregates. 
 The nature of the initial and primary stress elicited by PI’s is an important 
unanswered question. Roles for both a cytosolic, heat shock-like stress and ER stress are 
well documented (32, 33, 110). Through an unbiased, quantitative analysis of both cytosolic 
(Hsp72) and ER stress (Grp78, CHOP) biomarkers, our data argue that in pancreatic cancer 
cells, the cytosolic stress component is greater. Induction of Grp78 and CHOP expression by 
BZ was minimal when to compared to a classic ER stressor such as TG; conversely BZ was 
a strong inducer of Hsp72 expression whereas TG was not. This model of BZ-induced stress 
is supported by our kinase activation data, indicating that HRI is more strongly activated 
than PERK. The concept of BZ as a cytosolic stressor that primarily activates HRI is 
supported by work detailing similar activation of HRI in erythroid cells following exposure 
to other cytosolic stressors such as heat shock, arsenic, and osmotic stress (45). HRI has also 
been linked to BZ-induction of stress granule formation (131). The strong shifts seen in total 
HRI bands upon BZ exposure (Fig. 3.16) are consistent with activation of HRI by extensive 
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autophosphorylation (in particular Thr485) (132). The mechanism by which BZ activates 
HRI likely resembles activation of PERK during ER stress. HRI exists in inactive complexes 
with molecular chaperones (Hsc70/Hsp72, Hsp90).  Upon sensing proteotoxic stress, the 
repressive chaperones leave HRI to bind misfolded proteins, leaving HRI to become 
activated. Overall, our model suggests that the shift towards misfolded protein accumulation 
is the initial stress elicited by BZ, and subsequently HRI is the primary kinase activated. 
This is contrary to a recent high-profile study arguing that amino acid depletion was the 
primary stress caused by PI’s, and that this led to GCN2 activation and ultimately CHOP-
dependent cell death (86). It is highly plausible that by blocking the proteasome, the pool of 
free amino acids would be perturbed; however, we found no GCN2 activation by BZ in our 
experiments (Fig. 3.16). In addition, we were unable to prevent BZ-induced cell death by 
CHOP knockdown, suggesting that CHOP acts differently in our cell lines (Fig. 3.15) 
 Taken together, our data suggest targeting HRI as a novel strategy to prevent 
cytoprotective eIF2α phosphorylation and overcome resistance to BZ. HRI-/- mice display 
normal, fertile phenotypes, with the only complications being minor hematologic defects 
(44). This points to HRI as potentially amenable to pharmacologic inhibition; presently no 
specific HRI inhibitors exist, and our study supports the development of such inhibitors for 
combination with PI’s. 
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Chapter 4.  INDUCTION OF HSP72 AS A 
CYTOPROTECTIVE RESPONSE TO BORTEZOMIB 
IN BLADDER CANCER CELLS 
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4.1 Introduction 
 The heat shock response (HSR) is strongly activated by proteasome inhibition. Many 
similarities exist between heat shock and proteasome inhibition: they both function primarily 
to increase the titer of misfolded proteins within the cytosol. The major chaperone induced 
by the HSR is an inducible isoform of the Hsp70 family; Hsp72, which functions to ensure 
proper protein folding and prevent aggregation. In addition, other cytoprotective functions 
have been attributed to Hsp72 such as lysosomal stabilization and inhibition of apoptosis 
(133-135). The centrality of Hsp72 as a cytoprotective factor in response to stress is 
highlighted by its extraordinary conservation throughout evolution, existing relatively 
unchanged from E. coli to mammals (136). The Hsp70 family of chaperones contains 
multiple isoforms, although not all are part of the inducible HSR. In order to clarify this 
discussion, a brief outline of nomenclature is useful. In humans, up to 13 different isoforms 
have been proposed – HSPA1A, HSPA1B, HSPA1L, HSPA2, HSPA5, HSPA6, HSPA7, 
HSPA8, HSPA9, HSPA12A, HSPA12B, HSPA13, and HSPA14 (137). Of these, six 
function in the cytosol and nucleus, whereas two are localized to the ER and mitochondria 
(HSPA5 and HSPA9, respectively). HSPA5 is better known as Grp78/BiP, and will be 
referred to as such. Of the cytosolic HSPA members, HSPA2 is expressed primarily in both 
the testis and the brain, whereas HSPA1L is almost exclusively expressed in the testis. 
Conversely, HSPA8 is constitutively expressed in most tissues, and is referred to as heat 
shock cognate 70, or Hsc70. Little is known about HSPA12-HSPA14. Importantly, only 
three of the HSPA family members are known to be stress-inducible: HSPA1A, HSPA1B, 
and HSPA6. HSPA1A and HSPA1B genes are located adjacent to one another on  
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Table 1  HSP70 superfamily: HSPA (HSP70) and HSPH (HSP110) families 
 
Gene name Protein name Old names Human gene ID
 Mouse ortholog ID 
 
HSP A 
1 
 
 
HSPA1A 
 
 
HSPA1A 
 
 
HSP70-1; HSP72; HSPA1 
 
 
3303 
 
 
193740 
2 HSPA1B HSPA1B HSP70-2 3304 15511 
3 HSPA1L HSPA1L hum70t; hum70t; Hsp-hom 3305 15482 
4 HSPA2 HSPA2 Heat-shock 70kD protein-2 3306 15512 
5 HSPA5 HSPA5 BIP; GRP78; MIF2 3309 14828 
6 HSPA6 HSPA6 Heat shock 70kD protein 6 (HSP70B′) 3310 X 
7 HSPA7a HSPA7 Heat shock 70kD protein 7 3311 X 
8 HSPA8 HSPA8 HSC70; HSC71; HSP71; HSP73 3312 15481 
9 HSPA9 HSPA9 GRP75; HSPA9B; MOT; MOT2; PBP74; mot-2 3313 15526 
10 HSPA12A HSPA12A FLJ13874; KIAA0417 259217 73442 
11 HSPA12B HSPA12B RP23-32L15.1; 2700081N06Rik 116835 72630 
12 HSPA13b HSPA13 Stch 6782 110920 
13 HSPA14 HSPA14 HSP70-4; HSP70L1; MGC131990 51182 50497 
HSP H      
1 HSPH1 HSPH1 HSP105 10808 15505 
2 HSPH2b HSPH2 HSPA4; APG-2; HSP110 3308 15525 
3 HSPH3b HSPH3 HSPA4L; APG-1 22824 18415 
4 HSPH4b HSPH4 HYOU1/Grp170; ORP150; HSP12A 10525 12282 
a Annotated as pseudogene, but possibly a true gene 
b Under consultation with HGNC and the scientific community 
 
Table 4.1. Hsp70 chaperone family proposed nomenclature. Systematic re-naming of 
known Hsp70 family chaperones, shown adjacent to traditional names found in the 
literature. 
 
*Reprinted by permission from Macmillan Publishers Ltd: [CELL STRESS & 
CHAPERONES], (137), copyright (2009). 
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chromosome 6 (6p21.3 region), and encode functionally identical proteins that differ in 
sequence by only two amino acids. Between the two, the HSPA1A isoform is typically 
expressed at levels 2-3 times higher than HSPA1B. For the purposes of this thesis, Hsp72 
will refer to the total protein encoded by the two isoforms, HSPA1A and HSPA1B.  
 Hsp72’s role in cancer is has been well documented (138, 139). Increased expression 
of Hsp72 is commonly found in human tumors (11), and is thought to help manage the stress 
of a malignant phenotype and offer resistance to apoptosis (133, 140). Notably, Hsp72 is 
strongly induced by certain chemotherapeutic agents, especially proteasome inhibitors (32, 
33). Induction of heat shock proteins is implicated in resistance to proteasome inhibitors 
such as bortezomib (BZ) (141, 142).  
Our group previously investigated the cytotoxic effects of BZ on bladder cancer cells 
within the context of combination therapy (143, 144). In this study, we sought to screen a 
larger panel of bladder cancer cells for sensitivity to BZ, and to determine cytoprotective 
mechanisms that may be contributing to BZ resistance. We identified the Hsp72 chaperone 
as one of the most highly induced genes in bladder cancer cells exposed to BZ, therefore, we 
hypothesized that Hsp72 induction likely was a potent inhibitor of BZ-induced cell death in 
bladder cancer. Here, we discovered that in a subset of bladder cancer cells, BZ robustly 
induced Hsp72 protein levels, but discovered that HSPA1A and HSPA1B mRNA expression 
differed dramatically between cell lines. Some cell lines (253JB-V and SW780) expressed 
both HSPA1A and A1B mRNA; however others (UM-UC10 and UM-UC13) expressed 
almost undetectable levels of HSPA1A but highly expressed the A1B isoform. This was 
found to be a result of decreased HSF1 binding at the HSPA1A promoter in these cells 
because of heavy DNA methylation in the region.  Knockdown of HSPA1B in UM-UC10 
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cells depleted Hsp72 protein levels and enhanced BZ sensitivity, whereas overexpression of 
HSPA1A in UM-UC10 and –UC13 raised total Hsp72 protein levels and inhibited BZ-
induced cell death. Knockdown of total Hsp72 sensitized resistant 253JB-V cells to 
bortezomib both in vitro and in vivo, and chemical inhibition of HSF1 also sensitized these 
cells in vitro. Overall, this study supports the further development of HSF1 and Hsp72 
inhibitors for cancer therapy, and also further investigation of the etiology and functional 
significance of HSPA1A promoter methylation in bladder and other solid tumors. 
 
4.2 Results 
4.2.1 Differential induction of HSPA1A in bladder cancer cells. We selected four 
representative human bladder cancer cell lines (253J B-V, SW780, UM-UC10, and UM-
UC13) for characterization of the molecular biological mechanisms that determine cellular 
responsiveness to the proteasome inhibitor bortezomib.  We first confirmed that the cell 
lines were heterogeneous with respect to their sensitivities to bortezomib-induced cell death 
as determined using propidium iodide staining and FACS analysis (PI-FACS) to measure 
loss of plasma membrane integrity (Fig. 4.2).  We then used whole genome mRNA 
expression profiling (Illumina platform) to identify the gene expression patterns associated 
with drug sensitivity and/or resistance.  Bortezomib induced strong dose-dependent 
upregulation of mRNA encoding the major inducible isoform of Hsp72 (HSPA1A) in the 
most bortezomib-resistant cell line (253J B-V) but not in the most drug-sensitive line (UM-
UC13) (Fig. 4.3).  We confirmed  these results using quantitative real-time RT-PCR, 
demonstrating that HSPA1A mRNA was strongly induced by bortezomib in 253JB-V and 
SW780 cells (~25-60 fold over untreated levels), whereas expression increased only slightly  
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Figure 4.1. Bortezomib-induced cell death in subset of bladder cancer cell lines. Effects 
of bortezomib on cell death.  Bladder cancer cell lines were incubated with or without 
100nM bortezomib for 24 hours and PI/FACS was used to quantify cell death.  Mean ± 
SEM, n = 3.  
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Figure 4.2 Bortezomib fails to induce 
HSPA1A in BZ-sensitive bladder cancer 
cells. A) Heat map depicting the effects of 
bortezomib on gene expression in 253J B-
V and UM-UC13 cells.  Cells were 
incubated with or without bortezomib for 6 
or 12 h, and global gene expression 
patterns were compared using the Illumina 
platform. (Arrow designates HSPA1A).  B) 
Validation of differential bortezomib-
mediated HSPA1A induction by 
quantitative real-time PCR. The same RNA 
samples from UM-UC13 and 253JB-V 
used in microarray analyses and an 
independent set of RNA samples were 
subjected to real-time PCR analysis to 
measure the level of HSPA1A expression. 
Values represent mean ± SEM (N≥3). 
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Figure 4.3 Comparison of HSPA1A mRNA and Hsp72 protein levels among bladder 
cancer cells. A) Effects of bortezomib on the mRNA expression of Hsp72 isoform HSPA1A 
in 4 bladder cancer cell lines (253JB-V, SW780, UM-UC10, UM-UC13). Cells were 
exposed to 30nM bortezomib for 6 h and HSPA1A was measured by quantitative RT-PCR. 
RQ = relative quantity (to GAPDH). Values represent mean ± SEM (N≥3) B) Effects of 
bortezomib on Hsp72 protein levels. Cells were incubated for 16-18 h with 30nM of 
bortezomib, and Hsp72 levels were measured in whole cell lysates by immunoblotting. Blots 
are representative of two independent experiments. 
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induced (~2-4 fold over untreated levels) in UM-UC10 and UM-UC13 cells (Fig. 4.4A). We 
also noticed very low basal HSPA1A mRNA expression in UM-UC10 and UM-UC13 cells  
(~50-250 fold lower than 253JB-V and SW780) and these differences were exacerbated 
upon bortezomib exposure such that HSPA1A expression levels were ~1000-3000 fold 
lower in UM-UC10 and UM-UC13 cells than in 253JB-V and SW780 (Fig. 4.4A). However, 
immunoblotting revealed comparable Hsp72 protein levels in all 4 cell lines (Fig. 4.4B). 
 
4.2.2 HSPA1B isoform compensates for loss of HSPA1A expression in UM-UC10 and UM-
UC13 cells.  Hsp72 is encoded by two independent genetic loci (HSPA1A and HSPA1B) 
that produce highly homologous protein products.  We therefore characterized HSPA1B 
expression in the HSPA1Alow cells.  We used primers specific for the two isoforms of 
Hsp72, HSPA1A and HSPA1B, as well as a primer that recognized both (pan) isoforms for 
comparison. Our data revealed that the HSPA1Alow cells (UM-UC10, UM-UC13) had higher 
expression of the HSPA1B isoform at baseline than did the HSPA1A-high cells (253JB-V, 
SW780) (Fig. 4.5A).  In addition, HSPA1B expression was more robustly induced following 
bortezomib exposure in the HSPA1Alow cells lines that lacked the A1A isoform (Fig. 4.5B). 
Importantly, expression measured by the pan-primer was similar across all four cell lines, 
corroborating the immunoblotting data (Fig. 4.4B). These data suggest that increased 
HSPA1B expression compensated for the lack of HSPA1A and accounted for the Hsp72 
protein expression in the UM-UC10 and UM-UC13 cells. 
  
4.2.3 Lack of HSPA1A inducibility in UM-UC10 and UM-UC13 cells is due to promoter 
methylation.  Heat shock factor-1 (HSF1) activation controls the global heat shock response  
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Figure 4.4 Increased HSPA1B expression compensates for loss of HSPA1A expression 
in UM-UC10 and UM-UC13 cells.  A. Basal expression of HSPA1A and HSPA1B 
isoforms across the four cell lines. B. Bortezomib-induced expression of HSPA1A and 
HSPA1B across the four cell lines. Specific primers for each isoform, as well as a pan-
primer that recognized both isoforms, were used to measure expression by quantitative RT-
PCR. Values represent mean + SE (n = 2). 
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and stress-induced upregulation of Hsp72 (145).  To test whether HSF1 expression was 
influencing differences in HSPA1A expression among our cell lines, we measured HSF1 
mRNA and protein levels in the 253JB-V (HSPA1Ahigh) and UM-UC13 (HSPA1Alow) cells.  
We observed modest differences in basal and BZ-induced HSF1 mRNA levels between 
253JB-V and UM-UC13 cells; specifically, 253JB-V showed a 2-fold increase in HSF1 
levels upon drug exposure, whereas UM-UC13 showed only ~1.3 fold increase, but had 2-
fold higher HSF1 mRNA expression at baseline than did 253JB-V (Fig. 4.6A). However, 
protein levels appeared essentially equal between both cell types (Fig. 4.6B).  Furthermore, 
other HSF1 targets were strongly induced, including the aforementioned HSPA1B (Fig. 4.5) 
and DNAJB1 (Hsp40) (Fig. 4.7) in the UM-UC10 and UM-UC13 cells, suggesting that there 
was no generalized defect in endogenous HSF1 activation in these cells.  We therefore 
reasoned that the UM-UC10 and UM-UC13 cells might possess specific defect(s) in HSF1-
mediated activation of the HSPA1A promoter.  Consistent with this idea, chromatin 
immunoprecipiation (ChIP) revealed that 253J B-V cells possessed higher levels of HSF1 
binding to the HSPA1A promoter at baseline and following bortezomib exposure than did 
UM-UC13 (~2-fold and ~5-fold higher, respectively) (Fig. 4.8). The fold-induction of HSF1 
binding by bortezomib was ~9-fold vs. ~4-fold in 253JB-V and UM-UC13, respectively.  
Analysis of the HSPA1A promoter using the UCSC Genome Browser revealed that it lies 
within a CpG island that is methylated in other cancer cell lines (Fig 4.9).  Using 
methylation-specific PCR, we confirmed that the HSPA1A promoter was strongly 
methylated in the UM-UC10 and UM-UC13 but not in the 253J B-V or SW780 cells 
(Fig.4.10A), which possibly accounted for defective bortezomib-induced HSPA1A  
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Figure 4.5 Examination of HSF1 mRNA and protein levels between HSPA1Ahigh and 
HSPA1Alow cells. Expression of HSF1.  253J B-V and UM-UC13 bladder cancer cell lines 
were exposed to bortezomib for 12 h and A) HSF1 mRNA expression (columns represent 
mean + SE n=2) and B) protein levels (representative of two independent experiments) were 
measured by quantitative RT-PCR and immunoblotting, respectively.   
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Figure 4.6 Bortezomib-induced expression of other HSF1 targets.  Effects of bortezomib 
on endogenous transcriptional targets of HSF1.  Bortezomib-resistant (253J B-V, SW780) 
and –sensitive (UM-UC10, UM-UC13) cells were incubated with 30nM bortezomib for 6 h 
and HSF-1 target induction was measured by quantitative RT-PCR.  Note that induction of 
other HSF1 targets (i.e., HSP40, HSP27) still occurred in HSPA1Alow UM-UC10 and UM-
UC13 cells.  Mean ± SEM, n = 3.  
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Figure 4.7 Reduced HSF1 binding to HSPA1A promoter region in sensitive cells. 
Chromatin immunoprecipitation (ChIP) analysis of HSF1 binding to the HSPA1A promoter.  
Note that basal and bortezomib-induced HSF1 binding is greatly reduced in the bortezomib-
sensitive UM-UC13 cells. 
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Figure 4.8 The HSPA1A promoter contains a CpG island that is commonly methylated 
in cancer.  A) HSPA1A gene locus on Chromosome 6. Specific location is 6p21.3. B) 
UCSC Genome Browser screenshot depicting a CpG island (dark green bar) at HSPA1A 
consensus promoter regions in multiple cell lines (red bars). Below, DNA methylation 
analysis of the HSPA1A promoter region across multiple cell lines and tissues types. 
Unmethylated= green; 50% methylated = yellow; 100% methylated= red. Note that 8 out of 
9 cell lines with significant methylation (orange-red color) were derived from human 
tumors.  
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Figure 4.9 Methylation of the HSPA1A promoter in bortezomib-sensitive human 
bladder cancer cells.  A) Methylation-specific PCR was used to assess chromatin 
methylation in drug-sensitive (UM-UC10, UM-UC13) and drug-resistant (253J B-V, 
SW780) cell lines as described in Materials and Methods.  m, methylated; u, unmethylated. 
B) The DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine restores HSPA1A 
expression in bortezomib-sensitive cells.  Cells were incubated with 5 µM 5-AC for 5 days 
and then incubated with or without 30nM bortezomib for 6 h, and HSPA1A expression was 
measured by quantitative real-time PCR.  Mean ± SEM, n = 3.   
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induction.  To directly test this possibility, we examined the effects of the histone 
methyltransferase inhibitor 5-aza-2’-deoxycytidine on basal and bortezomib-induced 
HSPA1A mRNA levels in the UM-UC10 and UM-UC13 cells.  The inhibitor induced large  
increases in both basal and proteasome inhibitor-induced HSPA1A levels in both 
bortezomib-sensitive cell lines (Fig. 4.10B).  Together, these results demonstrate that 
chromatin methylation is responsible for the defective HSPA1A induction observed in UM-
UC10 and UM-UC13 cells. 
 
4.2.4 Modulation of HSPA1A and HSPA1B expression in the HSPA1Alow cells. Since UM-
UC10 and UM-UC13 lacked HSPA1A expression, we examined whether replacing the 
HSPA1A isoform would promote bortezomib resistance. To address this, we stably 
overexpressed HSPA1A in both UM-UC10 and -UC13 cells using a lentiviral vector.  
HSPA1A mRNA expression was confirmed using qRT-PCR and Hsp72 total protein 
increases by immunoblotting (Fig. 4.11A). HSPA1A overexpressing cells and empty vector 
transduced cells were then exposed to bortezomib and we discovered that overexpression 
significantly reduced bortezomib-induced cell death (Fig. 4.11B). Conversely, because UM-
UC10 and -UC13 cells appeared to be relying solely on HSPA1B mRNA for Hsp72 protein 
expression, we hypothesized that these cells may be particularly susceptible to targeting of 
HSPA1B. To test this, we used siRNA to transiently silence HSPA1B in UM-UC10 cells. 
Analysis of knockdown efficiencies revealed that the commercially available siRNAs cannot 
specifically target individual isoforms (i.e., siHSPA1A silenced HSPA1B) (Fig. 4.12A). 
Nonetheless, a combination of siHSPA1A and siHSPA1B sequences yielded the best 
(though not complete) overall knockdown of the A1B isoform at both the RNA and protein  
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Figure 4.10 Overexpression of HSPA1A reduces bortezomib-induced cell death in 
HSPA1Alow cells. A) Effects of enforced HSPA1A overexpression on HSPA1A levels in 
UM-UC10 and UM-UC13 cells.  Cells were stably transduced with a lentiviral HSPA1A 
expression construct, and HSPA1A levels were measured by quantitative RT-PCR.  Mean ± 
SEM, n = 3. Protein levels of Hsp72 were measured by immunoblotting (blots representative 
of two independent experiments). B) Effects of HSPA1A overexpression on bortezomib-
induced cell death.  Cells transduced with empty vector (NT) or with the HSPA1A 
expression construct were exposed to 30 nM bortezomib for 24 h and plasma membrane 
integrity was measured by trypan blue uptake.  (The presence of RFP in the expression 
construct prevented our use of the PI/FACS cell death assay.)  Mean ± SEM, n = 3. *, 
p<0.02 
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level (Fig. 4.12B).  Using this strategy, we confirmed that blockade of HSPA1B induction 
sensitized UM-UC10 cells to bortezomib (Fig. 4.13). 
 
4.2.5 Hsp72 induction inhibits bortezomib-induced cell death.  To more directly determine 
whether bortezomib-induced Hsp72 upregulation promoted resistance, we stably knocked 
down Hsp72 in 253JB-V bortezomib-resistant cells using a lentiviral shRNA vector. 
Baseline HSPA1A mRNA levels were reduced by more than 75% in the cells, but shRNA-
mediated suppression of HSPA1A mRNA (Fig. 4.14A) and Hsp72 protein (Fig. 4.14B) was 
less impressive following exposure to bortezomib, presumably because the proteasome 
inhibitor produced such a strong upregulation of Hsp72.  Nonetheless, stable Hsp72 
knockdown significantly enhanced bortezomib-induced loss of plasma membrane integrity 
as measured by propidium iodide uptake (Fig. 4.14C).  Previous studies concluded that 
Hsp72 induction serves a cytoprotective function within the integrated stress response (ISR) 
by stabilizing lysosomes (134).  As such, we compared the effects of bortezomib on 
lysosomal integrity in the 253JB-V cells transduced with control vector (253JB-V NT) or 
the KD9 HSPA1A-specific shRNA construct.  Bortezomib had little to no effect on 
lysosomal integrity in the 253JB-V NT cells but induced strong, concentration-dependent 
loss of lysosomal integrity in the 253JB-V-KD9 cells (Figure 4.15). Together, these results 
confirm that bortezomib-induced Hsp72 induction functions to promote lysosomal integrity 
and to inhibit cell death.  Finally, we examined whether pharmacologic HSF1 inhibition 
would also promote bortezomib-induced cell death.  The chemical HSF1 inhibitor KNK-437 
strongly attenuated bortezomib-induced HSPA1A induction (Fig. 4.16A) and promoted cell  
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Figure 4.11 Knockdown of HSPA1B in HSPA1Alow cells. Knockdown of HSPA1B in 
UM-UC10 cells. A) knockdown efficiencies of siRNA against HSPA1A, HSPA1B, or both 
isoforms as measured by quantitative RT-PCR following exposure to 30nM bortezomib for 
6 h. B) corresponding knockdown of Hsp72 protein levels by the difference siRNA 
sequences following exposure to 30nM BZ for 14 h. Data are representative of two 
independent experiments. 
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Figure 4.12 Knockdown of HSPA1B enhances BZ-induced cell death in HSPA1Alow 
cells. Effect of HSPA1B knockdown on bortezomib-induced cell death in UM-UC10 cells. 
Following 72 h knockdown, cells were exposed to 30nM bortezomib for 24 h and cell death 
measured by PI/FACS analysis. Values represent mean + SE (n=3).*P<0.05. 
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Figure 4.13 Knockdown of HSPA1A enhances bortezomib sensitivity.  A)  Effects of 
stable HSPA1A knockdown on basal and bortezomib-induced HSPA1A expression.  253J 
B-V cells were transduced with a non-targeting (NT) or HSPA1A-specific (KD5, KD9) 
lentiviral shRNA constructs as described in Materials and Methods.  Cells were then 
incubated with or without indicated concentrations of bortezomib for 6 h and HSPA1A 
expression was measured by quantitative RT-PCR.  Mean ± SEM, n = 3. B) Effects of stable 
HSPA1A knockdown on HSP72 protein levels.  Cells were incubated for 12 h with indicated 
concentrations of bortezomib (nM), and HSP72 levels were measured in whole cell lysates 
by immunoblotting. C) Effects of stable HSPA1A knockdown on bortezomib-induced cell 
death.  Cells were incubated with the indicated concentrations of bortezomib for 48 h and 
PI/FACS analyses were used to quantify cell death.  Mean ± SEM, n = 3. *, p<0.01 
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Figure 4.14 Hsp72 knockdown promotes loss of lysosomal integrity.Effects of stable 
HSPA1A knockdown on lysosomal membrane integrity.  A) Cells were exposed to the 
indicated concentrations of bortezomib for 12 h prior to staining with Lysotracker Red, and 
loss of red fluorescence was measured by FACS. Cells with loss of lysosomal integrity were 
designated as “Lysotracker-pale” cells by the gated regions. B) Results were quantified as % 
Lysotracker-pale cells (mean + SEM; n=3). *, P < 0.03. 
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Figure 4.15 Pharmacologic inhibition of HSF1 promotes bortezomib sensitivity in 
vitro.  A)  Effects of KNK-437 on bortezomib-induced HSPA1A induction.  Bortezomib-
resistant 253J B-V cells were exposed to 25 µM KNK-437 with or without 100nM 
bortezomib for 12 h, and HSPA1A levels were measured by quantitative RT-PCR.  Mean ± 
SEM, n = 3. A)  Effects of KNK-437 on cell death.  253J B-V cells were exposed to 25 or 
50 µM KNK-437 in combination with 30 or 100nM bortezomib for 48 h, and loss of plasma 
membrane integrity was quantified by PI/FACS.  Mean ± SEM, n = 3. *, P<0.05. 
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death (Fig. 4.16B) in the 253JB-V cells.  These data support the idea that chemical inhibitors 
of HSF1 and/or Hsp72 can be used to promote bortezomib-induced cell death. 
 
4.2.6 Hsp72 knockdown promotes bortezomib-induced tumor growth inhibition in vivo.  In 
a final series of experiments we examined whether stable Hsp72 knockdown would promote 
the growth-inhibitory effects of bortezomib in 253JB-V tumors in vivo.  We established 
subcutaneous tumors using 253J B-V cells transduced with either the non-targeting (NT) or 
Hsp72-specific KD9 shRNA constructs and dosed animals with bortezomib (1 mg/kg, the 
MTD) twice weekly via i.v. injection.  Using quantitative real-time RT-PCR, we confirmed 
that bortezomib increased HSPA1A mRNA levels in vivo and that the shRNA construct 
inhibited these effects (Fig. 4.17A).  The untreated 253JB-V KD9 tumors displayed 
somewhat slower tumor growth than did the 253JB-V NT tumors, but the differences did not 
reach statistical significance.  Biweekly therapy with bortezomib had no significant effects 
on the growth of the control 253JB-V.NT tumors (Fig. 4.17B), consistent with our previous 
findings (143).  Conversely, bortezomib almost completely suppressed the growth of the 
tumors derived from the 253JB-V cells transduced with the HSPA1A-specific shRNA 
construct (Fig. 4.17B).  
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Figure 4.16 Knockdown of HSPA1A promotes bortezomib-induced growth inhibition 
in vivo.  A) Effects of bortezomib on HSPA1A induction.  Animals were injected twice with 
1 mg/kg bortezomib (3 days apart), tumor RNA was harvested, and HSPA1A expression 
was measured by quantitative RT-PCR.  Mean ± SEM, n = 3.  B)  Effects of bortezomib on 
tumor growth.  Athymic nude mice were inoculated s.c. with 253JB-V.KD9 or 253JB-V.NT 
cancer cells. When tumors became palpable (5-7 days), the mice were treated i.v. biweekly 
with bortezomib at 1mg/kg/dose or with saline control. Tumor volumes were measured 
twice a week after the start of treatment. Values represent mean ± SE (N=5). 
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4.3. Discussion 
Our study is the first to specifically examine Hsp72 modulation in combination with 
bortezomib in bladder cancer cells in vitro and in vivo. The data demonstrate that Hsp72 
protects cancer cells from proteasome inhibitor-induced stress and cell death. We propose 
that the cytoprotective effects of Hsp72 are in part due to its known role in promoting 
lysosomal integrity (134, 146), as 253JB-V cells stably transduced with Hsp72-specific 
shRNA showed dramatic increases in lysosomal instability over non-targeting control 
transduced cells. Proteasome inhibition activates autophagy and increases flux through the 
autophagy-lysosomal system as a compensatory mechanism.  It is likely that the increased 
lysosomal instability caused by Hsp72 depletion has deleterious effects on autophagy 
function, which is thought to aid in clearing misfolded protein aggregates during proteotoxic 
stress.  
Furthermore, we discovered that among the four cell lines tested,bortezomib-
sensitive cells displayed much lower levels of both basal and drug-induced HSPA1A than 
bortezomib-sensitive cells (Fig. 4.4). This was due to methylation of the HSPA1A promoter 
region in the sensitive cells, which prevented HSF1 binding and suppressed HSPA1A 
expression (Figs. 4.8 - 4.10). Intrigued by these data, we expanded our analysis to include a 
total of 20 bladder cancer cell lines in hopes of revealing a correlation between lack of 
HSPA1A expression and BZ sensitivity. However, the correlation was not apparent, either 
using basal or BZ-induced expression (Fig. 4.18 A,B). Overall, approximately 40% of the 
cell lines had extremely low HSPA1A expression, suggesting that methylation of the 
HSPA1A promoter region may be prevalent in bladder cancer. It is unclear why HSPA1A 
promoter methylation would be propagated in cancer, but  
 
105 
 
A 
Basal Hsp72 expression vs. BZ senstivity
R
Q
 o
f H
SP
A1
A 
(t
o 
G
AP
D
H
)
%
 PI-positive cells
25
3J
B-
V
UM
-U
C1
8
UM
-U
C1
5
UM
-U
C1
1
1A
6
HT
13
76
UM
-U
C1
SW
78
0
J8
2
UM
-U
C9
RT
11
2
RT
4V
6
UM
-U
C1
2
T2
4
UM
-U
C3
UM
-U
C1
0
SC
aB
ER
UM
-U
C5
UM
-U
C1
4
UM
-U
C1
3
0.00
0.05
0.10
0
20
40
60
80
100
1
2
3
4
basal HSPA1A expression BZ-induced cell death   
B 
Inducible Hsp72 expression vs. BZ senstivity
R
Q
 o
f H
SP
A1
A 
(t
o 
G
AP
D
H
)
%
 PI-positive cells
25
3J
B-
V
UM
-U
C1
8
UM
-U
C1
5
UM
-U
C1
1
1A
6
HT
13
76
UM
-U
C1
SW
78
0
J8
2
UM
-U
C9
RT
11
2
RT
4V
6
UM
-U
C1
2
T2
4
UM
-U
C3
UM
-U
C1
0
SC
aB
ER
UM
-U
C5
UM
-U
C1
4
UM
-U
C1
3
0.00
0.05
0.10
0
20
40
60
80
100
50
100
150
200
BZ-induced
HSPA1A expression
BZ-induced cell death
 
Figure 4.17 Relationship between basal and inducible Hsp72 expression and 
bortezomib sensitivity. A) Basal expression of Hsp72 (black) vs. BZ-induced cell death 
(red). B) BZ-induced Hsp72 expression (black) vs. BZ-induced cell death (red). 
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Figure 4.18 Relationship between basal Hsp72 expression and cisplatin sensitivity. 
Basal expression of Hsp72 (black) vs. cisplatin-induced apoptosis (red). For Hsp72 
expression, cells were exposed to 30nM BZ for 6h and then HSPA1A expression measured 
by RT-PCR. For cisplatin-induced DNA fragmentation (% sub-diploid), cell were exposed 
to 10uM cisplatin for 48h, then DNA fragmentation was measured by PI-FACS. 
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perhaps the CpG island surrounding the promoter becomes methylated as part of global 
epigenetic alterations involved in bladder cancer progression  (147, 148). In gastric cancer, 
the Epstein-Barr virus has been shown to upregulate DNA methyltransferase (DNMT1) and 
promote methylation of the Hsp72 promoter region (149). HSPA1A promoter methylation 
in bladder cancer bears further investigation as a potential biomarker of sensitivity to other 
chemotherapeutic drugs such as cisplatin (Fig. 4.13). Importantly, we demonstrated that 
bladder cancer cells lacking HSPA1A depend heavily on HSPA1B expression to maintain 
Hsp72 protein levels. Based on these results, selective targeting of HSPA1B in cells with 
hypermethylation at the HSPA1A promoter could confer synthetic lethality.  
The involvement of molecular chaperones and the heat shock response in cancer is 
an area of intense interest. Hsp90, through its role as a molecular “holdase”, interacts with 
numerous oncoproteins to ensure proper function and interactions (150). Pioneering work 
with Hsp90 inhibitiors validated chaperones as attractive targets, and these have displayed 
some clinical activity in cancer (151). Conversely, the development of Hsp72 inhibitors is 
noticeably lacking because of difficulty thus far in targeting the ATPase domain (152). 
Recent work demonstrated that the small molecule 2-phenyethynesulfonamide or pfithrin-µ 
(PES) is a relatively specific inhibitor of Hsp72, binding the C-terminal substrate-binding-
domain and preventing key interactions with co-factors such as Hsp40, CHIP, and Bag-1 
while avoiding interactions with other chaperones such as constitutive Hsc70 and Hsp90 
(111). PES also interacts with p53, and likely has other pleiotropic effects, making it 
unsuitable for use in patients, but it nonetheless provides a rationale for targeting the C-
terminus substrate-binding-domain as an alternative approach to inhibiting Hsp72’s 
functionality. Overall, our study supports the further development of Hsp72 inhibitors for 
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single agent and combination therapy in solid tumors; Hsp72 is an attractive, tumor-specific 
target because of its low expression unstressed normal cells versus high expression in 
stressed cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: EVALUATION OF THE EFFECTS OF A 
SELECTIVE HDAC6 INHIBITOR ON PROMOTING  
BORTEZOMIB-INDUCED CANCER CELL DEATH 
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5.1 Introduction 
 Histone deacetylase (HDAC) proteins are typically classified into three major groups 
based on evolutionary relationships and homology to yeast deacetylases (153). Class I 
HDACs consist of HDAC1, HDAC2, HDAC3, and HDAC8, while Class II includes 
HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10. Class III HDACs are 
somewhat distinct from the two classical HDAC groups, and consist of silent information 
regulator 2 (Sir2) family members, better known as sirtuins (SIRTs) (154). HDAC6 is 
unique among Class I and II HDACs both structurally and functionally (Figure 5.1). In 
addition to being the only HDAC with two deacetylase domains (DD1,2), HDAC6 contains 
two nuclear export signals (NES1-2) as well as a tetradecapeptide repeat-cytoplasmic 
anchoring domain (SE14), contributing to its almost exclusive cytosolic localization. 
HDAC6 also uniquely contains a zinc-finger ubiquitin-binding domain (UBD) near its C-
terminus. Thus, HDAC6 would more aptly be referred to as a “protein deacetylase”, as it 
almost exclusively targets cytosolic non-histone substrates (Table 5.1), with no known 
effects on nuclear histones.  
Of the cytosolic substrates, α- tubulin is the best characterized; pharmacologic 
inhibition or genetic silencing of HDAC6 rapidly and robustly increases the levels of 
acetylated α-tubulin. Acetylation of tubulin confers a more stable, rigid microtubule network 
(155, 156) and thus has important consequences on intracellular trafficking, mitotic division, 
and cellular adhesion/motility. Accordingly, in addition to its role in shuttling cargo for 
degradation, recent literature also implicates a critical role for HDAC6 in cell migration and 
invasion. Seminal work from Tso-Pang Yao’s group demonstrated that  
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Figure 5.1 Functional domains of HDAC6 protein. A potential nuclear localization signal 
(NLS) flanks a nuclear export signal (NES1) near the N-terminus (157). However, the 
presence of another NES (NES2) as well as a cytosolic anchoring signal (SE14) collectively 
keep HDAC6 localized to the cytosol. Two catalytic deacetylase domains (DD1&2) interact 
with substrates including α-tubulin, Hsp90, and cortactin. Finally, a zinc-finger ubiquitin-
binding domain (UBD) near the C-terminus allows HDAC6 to directly bind ubiquitylated 
proteins.  
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Table 5.1 HDAC6 substrates, interacting proteins, and related biological functions. 
*Reprinted from Trends in Cell Biology, 116, Agustin Valenzuela-Fernandez, J. Roman 
Cabrero, Juan M. Serrador, Francisco Sanches-Madrid, HDAC6: a key regulator of 
cytoskeleton, cell migration and cell-cell interactions, 291-297, Copyright (2008), with 
permission from Elsevier. Reference # (158). 
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HDAC6 deacetylase activity was necessary for chemotactic-induced cell invasion across a 
matrix (159). HDAC6 inhibition leading to hyperacetylated tubulin was also shown to  
negatively affect the capability of cells to undergo dynamic cell-cell adhesions, which is 
necessary for migration (160).  The actin cytoskeletal network is also targeted by HDAC6 
through deacetylation of cortactin. Cortactin is an F-actin interacting protein that stimulates 
actin polymerization, and hyperacetylation of cortactin by HDAC6 inhibition was found to 
reduce association with F-actin and inhibit cellular motility (161). Related to its cytoskeletal 
functions, HDAC6 has also been linked to a fascinating structure called the primary cilium. 
A single primary cilium exists in most mammalian cells (although it is commonly lost upon 
malignant transformation), arising from centrioles and playing a role in Hedgehog, Wnt, and 
other essential signaling pathways (162). HDAC6 was found to be phosphorylated by the 
Aurora A kinase and to regulate disassembly of primary cilia in human retinal pigment 
epithelial cells (163).  
  Another important substrate of HDAC6 is the Hsp90 chaperone protein (164). As 
previously discussed, Hsp90 interacts with numerous client proteins, many of which are 
important for cancer, and these interactions are strongly influenced by its acetylation status, 
which is modulated by HDAC6. HDAC6 also appears to plays a role in controlling 
activation of the heat shock response (HSR) through dissociation of the Hsp90-HSF1 
complex. At steady state, HDAC6 and the ATPase p97/VCP exist bound to the Hsp90-HSF1 
repressive complex; upon stress, HDAC6 leaves to bind ubiquitylated proteins, and 
p97/VCP uses its segregase activity to disrupt the Hsp90-HSF1 interaction, allowing HSF1 
to trimerize and translocate to the nucleus to induce the HSR (165). The capability of 
HDAC6 to directly bind both single and poly-ubiquitin chains via its C-terminal UBD also 
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has important functional implications for proteostasis. As previously discussed, HDAC6’s 
ubiquitin-binding ability coupled with its ability to associate with dynein motor complexes 
allows it to coordinate the transport of misfolded/ aggregated proteins along microtubules to 
perinuclear aggresomes (Section 1.3.2d). HDAC6 has also been found to regulate autophagy 
through its role in coordinating an F-actin network that promotes fusion of autophagosomes 
and lysosomes (166).  
 The myriad functions of HDAC6 in response to proteotoxic stress has led to the 
concept of HDAC6 as a novel “stress surveillance factor” (167) . Interestingly, an essential 
role for HDAC6 in tumorigenesis was also proposed (168), which supports the idea that 
cancer cells pirate stress-coping mechanisms to promote their malignant phenotype. Along 
these lines, HSF1 has also been found to promote tumorigenesis (2).  
 A concerted effort has been made over the past decade to discover and develop 
HDAC6-specific inhibitors for use in cancer and other diseases. Pan-HDAC inhibitors such 
as tricostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA/ clinically: Vorinostat) 
inhibit HDAC6, but also inhibit other Class I and II HDACs making it difficult to attribute 
functions to any specific HDAC. The first major success in targeting HDAC6 directly came 
from a large chemical library screen that identified a compound called tubacin as a relatively 
selective inhibitor of HDAC6 and tubulin deacetylation (169). Other compounds soon 
followed with greater selectivity, such as tubastatin A (170), NK84 (171), and LBH589 
(172).  
 Here we compared the effects of a selective HDAC6 inhibitor (Compound A) to 
those of type I-selective (MS275) and pan-selective (SAHA) HDAC inhibitors on pancreatic 
and bladder cancer cell viability, alone and in combination with the proteasome inhibitor 
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bortezomib (BZ). We hypothesized that the selective HDAC6 inhibitor would have the 
strong  effects on BZ-induced proteotoxicity, and enhance BZ-induced cell death. To 
validate chemical inhibitor data, we also genetically silenced HDAC6 and Type I HDACs in 
select cell lines. Overall, our data argue against a unique role for HDAC6 in promoting 
survival following proteasome inhibition, but rather support the continued evaluation of 
Type I HDAC inhibitors in combination with PIs.  Instead, Compound A was a potent 
inhibitor of tumor cell invasion, supporting its continued development as an inhibitor of 
metastasis. 
 
5.2 Results 
5.2.1 Validation of on-target effects of Compound A- We first sought to determine the 
specificity of the novel HDAC6-selective inhibitor Compound A by comparing its effects on 
protein acetylation (acetylated α-tubulin vs. acetylated histone H3) by immunoblotting (Fig. 
5.2). We directly compared the effects of Compound A (Cpd. A) to those of a class I-
specific inhibitor (SNDX/MS-275). Dose-response analyses revealed that concentrations of 
Cpd A as low as 0.1µM (100nM) were sufficient to increase levels of acetyl-tubulin, 
whereas concentrations as high as 10µM had no effects on acetyl-H3 levels, indicating that 
Cpd. A has robust and selective effects on HDAC6. MS-275, on the other hand, produced 
strong increases in acetyl-H3 levels at 5-10µM but little to no  effects on levels of acetyl-
tubulin. Overall these data point to Cpd. A as a potent and selective HDAC6 inhibitor. 
5.2.2 Effects of the HDAC inhibitors on bortezomib-induced cell death- To evaluate the 
toxicity of Cpd. A as a single agent in our cancer cell lines, we used the colorimetric MTT  
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A  Compound A 
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Figure 5.2 Structure and specificity of Compound A. A) Chemical structure of 
Compound A, B)253JB-V human bladder cancer cells were treated for 24h with a dose 
response (0.1-10µM) of either Compound A or SNDX-275 (MS-275) and levels of 
acetylated and total histone H3 and α-tubulin were measured by immunoblotting. Compound 
A increased levels of acetyl-tubulin at 0.1µM but had no effect on acetyl-H3 at doses up to 
10µM.  
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assay to examine its concentration-dependent effects of Cpd. A on cell growth and 
metabolic activity. For comparison, we also included the pan-HDAC inhibitor SAHA 
as well as the Class I-specific SNDX-275. Our data indicate that in the human pancreatic 
cancer line L3.6pl, SAHA and SNDX-275 decreased formazan salt production (an indicator 
of metabolically active, viable cells) at concentrations > 5µM, whereas formazan salt 
production was relatively unchanged by Cpd. A at concentrations up to 10µM (Fig. 5.3). To 
further investigate the toxicity of Cpd. A, we performed additional experiments measuring 
cumulative cell death (via outer membrane integrity) and apoptosis (via DNA 
fragmentation) across a panel of 10 human pancreatic cancer cell lines (Fig. 5.4). In both 
assays, Cpd. A induced minimal amounts of cell death and apoptosis (red columns, Fig. 
5.4A and B, respectively). Because of our interest in the ability of a selective HDAC6 
inhibitor to synergize with proteasome inhibitors, we combined Cpd. A, SNDX-275, or 
SAHA with BZ and measured growth inhibition, total cell death, and apoptosis. While Cpd. 
A showed significant enhancement of BZ-induced growth inhibition with the MTT assay in 
L3.6pl cells (Fig. 5.3), it did not significantly enhance cell death or apoptosis across the 
panel of pancreatic cancer cell lines (with the exception of the T3M4 line). Interestingly, 
SNDX-275, while slightly more toxic as a single agent, significantly augmented BZ-induced 
cell death in multiple cell lines (Fig. 5.4). In a subset of 3 pancreatic cell lines (Fig. 5.5), 
SAHA appeared to be more effective than either SNDX-275 or Cpd. A at enhancing BZ-
induced cell death. These effects were even more striking in a BZ-resistant bladder cancer 
cell line, 253JB-V, where both SNDX-275 and SAHA strongly sensitized cells to BZ-
induced death, measured by DNA fragmentation and outer membrane integrity at 24 and 48  
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Figure 5.3 Compound A does not cause significant growth inhibition as a single agent, 
but enhances growth inhibition in combination with BZ. L3.6pl human pancreatic cancer 
cells were exposed to indicated concentrations of SAHA (top), SNDX-275 (middle), or Cpd. A 
(bottom) alone or in combination with 10nM BZ for 48h. MTT reagent was added then solubilized, 
and optical density at 575nm was measured. Columns represent mean + SE (n=3; n=2 for SNDX-
275). 
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A 
B 
Figure 5.4 Effects of SNDX-275 vs. Cpd. A on BZ-induced DNA fragmentation and 
cumulative cell death in pancreatic cancer cell lines. Cells were exposed to compounds 
for 24h. A) DNA fragmentation (% subdiploid); B) outer membrane permeability (% PI-
positive) as measured by FACS. Columns represent mean + SE (n=3). Asterisks denote P <  
0.05 compared to BZ alone for indicated columns (*BZ+A vs. BZ; **BZ+SNDX-275 vs. 
BZ). 
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Figure 5.5  Comparison of Cpd. A with both SNDX-275 and SAHA alone and in 
combination with BZ.  CF-Pac1, L3.6pl, and T3M4 pancreatic cancer cells were exposed to 
indicated concentrations of compounds for 24h. A) DNA fragmentation (% subdiploid) or 
outer membrane permeability (% PI-positive) were measured by FACS. Columns represent 
mean + SE (n=3). Asterisks denote P <  0.05 compared to BZ alone (*BZ+A vs. BZ; 
**BZ+SNDX-275 vs. BZ; ***BZ+SAHA vs. BZ). 
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Figure 5.6 Effects of Compound A vs. SNDX-275 and SAHA alone and in combination 
with BZ in 253JB-V bladder cancer cells. Cells were exposed to the indicated doses of 
compounds for 24 and 48h and FACS was used to measure apoptosis and cumulative death 
by A) DNA fragmentation (% subdiploid) and B) outer membrane integrity (% nonviable), 
respectively. Columns represent mean + SE. Asterisks represent P< 0.05 (**BZ+SNDX-275 
vs. BZ; ***BZ+SAHA vs. BZ). 
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hours (Fig. 5.6). Compound A was not effective in combination with BZ in these cells 
either, showing that the results were not pancreatic cancer-specific. Overall, the data suggest 
that inhibitors of Class I HDACs are more potent than HDAC6 inhibitors in terms of 
augmenting the cytotoxic effects of PI’s in solid tumor cells.  
5.2.3 Knockdown of HDAC6 and Class I HDACs – To validate the data obtained with the 
chemical HDAC inhibitors, we next performed transient siRNA-mediated silencing of 
HDAC6 and HDACs 1,2, and 3 in T3M4 pancreatic cancer cells. Knockdown efficiencies 
were robust for each target (>70%), but surprisingly none of the siRNAs significantly 
sensitized cells to BZ (Fig. 5.7).  Though not statistically significant, it appeared that 
knockdown of HDAC1, either alone or combined with the knockdown of HDACs 2, 3, or 
both, enhanced BZ-induced cell death to a greater degree than did HDAC6 knockdown, and 
also to a greater degree than knockdown of HDACs 2 and 3 individually. Likewise, transient 
knockdown of HDAC6 in another pancreatic cancer cell line, L3.6pl, also provided little 
sensitization to BZ (Fig. 5.8). To confirm these results in a different model, we generated 
253JB-V cells with stably silenced HDAC6 and HDAC1 using lentiviral delivery short 
hairpin RNA (shRNA) in pGIPZ plasmids. Knockdown was confirmed at the RNA and 
protein level (Fig. 5.7A) and cells were interrogated for increased apoptosis (DNA 
fragmentation) in response to 48h BZ exposure (Fig. 5.7B). Here, stable knockdown of 
HDAC1 significantly sensitized 253JB-V cells to BZ, whereas HDAC6 knockdown did not 
enhance BZ-induced apoptosis. Overall, these data seem to suggest a critical role for 
HDAC1 in protecting cells from proteasome inhibitors, and partially explains our results 
suggesting SNDX-275 as a better combination strategy with PI’s than an HDAC6 inhibitor. 
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The mechanisms behind this sensitization are presently unknown, and are likely pleitropic 
due to the chromatin-modifications resulting from HDAC1 inhibition.  
5.2.4 Effects of HDAC6 inhibition on BZ-induced cell death in MM cells- Because the 
majority of literature on proteasome inhibitors and HDAC6 was generated in multiple 
myeloma models, we decided to compare the effects of Cpd. A and SNDX-275 alone and in 
combination with BZ in four different MM cell lines (U266, MM1, OPM2, and RPMI 8226) 
(Fig. 5.10). In contrast to SNDX-275, Cpd. A was relatively non-toxic as a single agent. 
When combined with BZ, Cpd. A showed moderately sensitization in each of the four cell 
lines, but this was not statistically significant. Alternatively, SNDX-275, when combined 
with BZ, showed clear sensitization in three out of the four cell lines. Overall, these data 
support the conclusions drawn from our solid tumor cells. 
5.3 Discussion 
 In this study, we demonstrate that the type I-selective HDAC inhibitor SNDX-275 is 
a more potent chemosensitizer than a novel HDAC6-selective inhibitor (Cpd. A) when the 
drugs are combined with the proteasome inhibitor bortezomib. Despite strong preclinical 
biological evidence for an essential role for HDAC6 in protein aggregate clearance, our data  
show that inhibiting these effects has modest impact on survival in multiple solid tumor and 
MM cell lines; rather, specific hematologic tumors such as MM may be a niche application. 
The role for HDAC6 as a regulator of aggresome formation (65) and autophagy (173) is 
clear. However, these processes are dependent not only on HDAC6’s catalytic activity but 
also its ubiquitin-binding capacity. At present, no small molecules have been developed to 
target the HDAC6 UBD (Fig. 5.1); rather, all current inhibitors target the catalytic domain(s) 
(including Compound A). This is a significant caveat, because HDAC6’s functions are only  
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Figure 5.7 Effects of HDACs 1, 2, 3 and 6 knockdown on BZ-induced cell death in 
T3M4 pancreatic cancer cells. A) HDACs were silenced for 48-72h, and qRT-PCR was 
used to determine relative quantities of each target to a control gene (PPIA). Columns 
represent mean +  SE (n=2). B) Following silencing, cells were exposed to 20nM BZ for 
24h, and apoptosis (% subdiploid) measured by FACS. Columns represent mean + SE (n=3). 
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Figure 5.8 Effects of HDAC6 knockdown on BZ-induced cell death in L3.6pl 
pancreatic cancer cells. A) HDACs were silenced for 48-72h, and qRT-PCR was used to 
determine relative quantities of each target to a control gene (PPIA). Columns represent 
mean +  SE (n=2). B) Following silencing, cells were exposed to 20nM BZ for 24h, and 
apoptosis (% subdiploid; left panel) or outer membrane permeability (% PI-positive; right 
panel) was measured by FACS. Columns represent mean + SE (n=3). 
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Figure 5.9 Comparison of HDAC1 vs. HDAC6 stable knockdown on BZ sensitivity in 
253JB-V bladder cancer cells. Cells were stably transfected with pGIPZ plasmids in 
lentiviral vectors and selected using antibiotics. A) Two different knockdown constructs 
were evaluated for protein knockdown of each target (left panel), and the most potent- 
HDAC6 #1 (red) and HDAC1 #2 (blue) were validated by qRT-PCR (right panel) Data is 
representative of at least 2 independent experiments. B) Stably transfected cells were 
exposed to 20nM BZ for 48h and DNA fragmentation (% subdiploid) was measured by 
FACS. Columns represent mean + SE (n=3). Asterisk denotes P <  0.05. 
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Figure 5.10 Effects of Compound A and SNDX-275 on BZ-induced death in MM cells. 
Cells were grown in suspension and then exposed to indicated concentrations of drugs for 
24h. FACS analysis was used to determine the percent apoptotic cells (% subdiploid) as 
evidenced by fragmented DNA. Columns represent mean + SE (n=3).  
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partially inhibited by the available chemical inhibitors. To address this, we used siRNA and 
shRNA knockdown to decrease expression of type I HDACs or HDAC6, and surprisingly, 
the results largely confirmed what we had observed with the chemical inhibitors, in that 
knockdown of HDAC1 had stronger effects on BZ-induced cell death than did knockdown 
of HDAC6.  
Our results contrast with published work using other HDAC6-selective inhibitors. 
Much of this work was done in MM models; for example tubacin, a moderately selective 
HDAC6 inhibitor, was found to enhance BZ-induced cell death in MM (174). However, it 
should be mentioned that the dose of tubacin used in this study (5 µM ) has off-target effects 
on Class I HDACs, as evidenced in a previous study by Haggarty, et al. in which as little as 
0.2µM of tubacin was enough to noticeably raise acetylated-histone H3 levels (169). 
Notably, data on the effects of tubacin exposure on acetylated-histone H3 levels were 
lacking in the Hideshima, et al. study (174). Recently, similar results were found in MM 
cells and xenografts using a novel more selective HDAC6 inhibitor known as ACY-1215 
(175). In solid tumor cells, the HDAC6-selective inhibitor NK84 displayed synergy with 
bortezomib in ovarian cancer (171), and our own group demonstrated that HDAC siRNA 
sensitized L3.6pl pancreatic cancer cells to bortezomib (used at higher concentrations than 
(104). Cumulatively, targeting HDAC6 has yielded consistent but not dramatic sensitization 
to PIs in multiple studies. Two possible explanations exist for why our results do not match 
the studies mentioned here. The first could be related to the chemical properties of 
Compound A; however, it seems to be a very selective and potent inhibitor of HDAC6 (Fig. 
5.2). The second could be related to the cell types used in this study (pancreatic and bladder 
cancer); thus far the only other solid tumor cells in which a selective HDAC6 inhibitor has 
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been tested in combination with PIs is ovarian cancer, which may express extremely high 
levels of HDAC6 (171).  
 Because of the somewhat disappointing results of Compound A in our pancreatic and 
bladder cancer cells, we sought to examine its activity in MM cells (Fig. 5.9). Here, 
Compound A was non-toxic as a single agent, but combination with BZ provided modest but 
consistent increases in cell death over BZ alone in 4 different MM cell lines. However, 
SNDX-275 was more potent at enhancing the effects of BZ in these cells as well, although 
significant toxicity with single-agent SNDX-275 was observed. This supports previous 
findings, and suggests that MM may be the most appropriate disease site for HDAC6 + 
proteasome inhibitor based therapy.  
 In our MM, pancreatic, and bladder cancer cells, the Type I and pan- HDAC 
inhibitors, SNDX-275 and SAHA, respectively, consistently enhanced BZ-induced cell 
death and displayed greater toxicity as single agents than did Compound A. HDAC 
inhibitor-mediated sensitization to PIs has also been reported previously in the literature in a 
variety of tumor types (125, 176-178). Whereas the rationale for combining HDAC6 
inhibitors with PIs is fairly clear, it is not presently understood how/why inhibition of Type I 
HDACs sensitizes cells to PIs (179). Furthermore, it is not clear whether Type I HDAC 
inhibitors sensitize cells to PIs, or vice versa. Indeed, recent data indicate that HDAC 
inhibitor-induced decreases in proteasome activity play a significant role in the cytotoxicity 
of HDAC inhibition (180). Operating under the hypothesis that HDACi’s sensitize cells to 
PIs, a couple of interesting studies have highlighted the role of HDAC1 in PI-induced death. 
Kikuchi, et al. demonstrated that knockdown of HDAC1 alone sensitized MM cells to BZ, 
whereas HDAC1 overexpression promoted resistance (181). Buglio, et al. found that 
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combinations of a novel HDAC1-selective inhibitor (MGCD0103) and BZ in Hodgkin’s 
lymphoma synergize to produce greater levels of cell death than either drug alone (182). 
Importantly, our results identify novel effects of Type I HDACs on protein 
aggregation/aggresome formation as a potential explanation for their activity in combination 
with PIs. The disruption of large aggresome-like structures seen with SNDX-275 could be a 
result of altered gene expression levels, or perhaps by shuttling of nuclear HDACs into the 
cytosol to directly interact with the aggresome machinery. Regardless, these results bear 
further evaluation and may lead to previously undiscovered roles for nuclear HDACs.  
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Chapter 6. CONCLUSIONS & FUTURE DIRECTIONS 
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 Taken together, the components of this thesis describe key new findings that expand 
the body of knowledge with respect to the consequences of proteasome inhibition in cancer. 
In this section, the central conclusions from previous chapters (Chps. 3-5) will be outlined, 
and future strategies by which to expand these discoveries will be discussed.  
 
6.1 Conclusions 
Chapter 3: Lack of inducible eIF2α phosphorylation is associated with 
sensitivity to bortezomib in pancreatic cancer cells. Here, the data led to several key 
conclusions. Firstly, I showed that the induction of eIF2α-P at clinically relevant doses of 
BZ is cytoprotective, and not cytotoxic (as other groups have argued). Based on my 
observations, the dose appears to be critical for observing this cytoprotective effect. High-
doses of PIs (e.g. >100nM of BZ) may overwhelm the cell too rapidly to for global 
translational repression by eIF2α-P to be useful; rather the pro-apoptotic actions of eIF2α-P-
induced transcription factors such as CHOP may become dominant under these conditions. 
Secondly, I identified a subset of pancreatic cancer cells that possess high levels of 
constitutive eIF2α-P in resting conditions. This was found to be controlled by the eIF2α 
kinase GCN2. Thirdly, we demonstrated that this phenotype adversely affected cellular 
response to BZ, and we found less efficient translation attenuation, increased protein 
aggregation, increased oxidative stress, and increased cell death upon BZ exposure in these 
cells. Lastly, I identified HRI, and to a lesser extent PERK, as the eIF2α kinases activated by 
BZ exposure, and showed that silencing of HRI alone and in combination with PERK 
sensitizes resistant cells to BZ.  
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Chapter 4: Hsp72 induction protects bladder cancer cells from bortezomib-
induced cell death. In this chapter, we conclude that modulation of Hsp72 in bladder cancer 
significantly affects the anti-cancer activity of BZ. Chemical inhibition of the HSR or direct 
silencing of Hsp72 enhanced the cytotoxic effects of BZ in vitro and in vivo, while 
overexpression of Hsp72 decreased BZ-induced cell death. We also discovered 
heterogeneity in expression of the major Hsp72 isoform (HSPA1A) in human bladder cancer 
cells; some cells expressed both HSPA1A and HSPA1B and robustly induced both genes 
following exposure to BZ, whereas others expressed nearly undetectable levels HSPA1A 
that could not be induced. This was due to methylation of the HSPA1A promoter region in 
these cells, which inhibited HSF1 binding. These HSPA1Alow cells compensated for their 
lack of A1A isoform expression by increasing expression of the HSPA1B isoform such that 
total protein levels of Hsp72 were similar to cells expressing both isoforms. When we stably 
overexpressed HSPA1A in HSPA1Alow cells, we found that this increased levels of Hsp72 
and partially protected these cells from BZ-induced cell death. Likewise, knockdown of 
HSPA1B in HSPA1Alow cells sensitized them to BZ. Overall, extremely low HSPA1A 
levels were present in approximately 40% of bladder cancer cell lines tested, indicating that 
methylation of the HSPA1A promoter may be fairly common in bladder cancer. However, 
low HSPA1A expression did not correlate with BZ sensitivity, presumably because of the 
compensation by HSPA1B. Collectively, our data provide support for functional redundancy 
between the A1A and A1B isoforms. 
 Chapter 5: Evaluation of the effects of a selective HDAC6 inhibitor on 
promoting bortezomib-induced cancer cell death. Here, we first concluded that 
Compound A was indeed selective for HDAC6 over Class 1 HDACs because it promoted 
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robust accumulation of acetylated tubulin while not affecting acetylated histone-H3 levels. 
However, we did not look at the acetylation levels of other HDAC6 substrates such as 
Hsp90 and cortactin, or acetylation levels of other histones, so this is an obvious limitation 
to this study. Secondly, our data demonstrated that inhibition of Class I HDACs via SNDX-
275 was more potent than Compound A at enhancing BZ-induced cell death as measured by 
both DNA fragmentation and plasma membrane permeatility. This observation was 
corroborated by similar results from both transient (siRNA) and stable (shRNA) silencing of 
HDAC6 vs. Class I HDACs, in which the knockdown of Class I HDACs (in particular 
HDAC1) appeared to have stronger effects on promoting BZ-induced cell death than did 
HDAC6 knockdown. However, genetic silencing of the Class I HDACs did not completely 
recapitulate the dramatic sensitization provided by the SNDX-275 chemical inhibitor, 
indicating that this drug may have other off-target effects that are essential for enhancing the 
activity of BZ. Class I HDAC inhibitors have been previously shown to cause ROS 
production, and based on my data from Chp. 3, this represents an attractive explanation as to 
why SNDX-275 increases the toxicity of BZ and other PIs (125). Collectively, these data 
lead us to the ultimate conclusion that HDAC6 is not an effective target for synergy with PIs 
in solid tumors. 
 
6.2 Future directions 
Chapter 3. Our study detailing the relationship between eIF2α phosphorylation and 
BZ sensitivity in pancreatic cancer provides two important discoveries that upon further 
experimental validation, could have measurable impact on the way PI’s are used clinically. 
The first promising idea is that of eIF2α-P as a biomarker for an underlying stress that may 
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render cancer cells more sensitive to PI’s. Having only used 10 cell lines in one tissue type, 
our data suggest a strong correlation between high basal eIF2α-P and PI-sensitivity, but it is 
premature to call this a “biomarker”. Further studies will need to be done comparing eIF2α-
P and BZ sensitivity in additional cancer cell lines (at least n=30), and 
immunohistochemical analysis of eIF2α-P levels in Velcade®-responsive and -unresponsive 
tumors would also be necessary (perhaps through tissue microarray). It is likely that 
constitutive eIF2α-P is merely a “readout” of a more global perturbation in intracellular 
homeostasis. We speculate that because GCN2 appears to control constitutive eIF2α-P, 
GCN2-related metabolic stress pathways may be contributing to eIF2α-P in our BZ-sensitive 
cells. Whole-genome expression profiling comparing expression levels of these pathways 
between BZ-sensitive and BZ-resistant cell lines could provide useful clues as to the origins 
of constitutive eIF2α-P and perhaps provide a multi-faceted genetic “signature” to predict 
sensitivity to PI’s. At present, the functional consequences of constitutive eIF2α-P in our 
sensitive cells are not clear. One would predict that high basal eIF2α-P would significantly 
decrease global rates of protein synthesis, and we found that CF-Pac1 and T3M4 cells 
incorporated ~20-25% less 3H-leucine than did Suit2 and mPanc96 cells (Fig. 3.5), 
indicating less active protein synthesis (although these differences were not statistically 
significant). However, basal expression levels of CHOP were not significantly different 
between cells with high or low eIF2α-P (Fig. 3.13), suggesting that the constitutive 
phosphorylation at steady state is not completely mimicking the effects of stress-inducible 
phosphorylation on downstream signaling pathways. To more carefully explore the function 
of basal/constitutive eIF2α-P in our pancreatic cancer cells, future experiments should 
include stable ovexpression of the GADD34 phosphatase cofactor, which should reduce 
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constitutive phosphorylation in our BZ-sensitive cells and perhaps restore inducible 
phosphorylation and decrease BZ-sensitivity. Alternatively, the constitutive eIF2α-P could 
be an adaptive response to cell stress that is important for survival in some cells, and in this 
case one would expect that GADD34 overexpression could promote spontaneous cell death. 
The second exciting discovery from Chapter 3 that bears further exploration is the 
identification of HRI as the primary BZ-activated eIF2α kinase in pancreatic cancer (and 
likely other solid tumor) cells. Further experiments directly measuring HRI phosphorylation 
are needed to confirm this activation (since no phospho-specific HRI antibodies are 
currently available, this would have to be done using immunoprecipiation with a phospho-
serine antibody). In addition, another key future experiment would be to probe HRI-/- MEFs 
for enhanced sensitivity to PI’s, similar to previous experiments using eIF2α mutant MEFs 
(Fig. 3.20). If our hypothesis regarding the centrality of the cytoprotective response elicited 
by HRI- eIF2α-P is correct, targeting HRI could be a potent strategy to overcome resistance 
to PI’s. Kinases are among the most “druggable” targets and such approaches have proven 
effective in targeting cancer (183). Interestingly, HRI-/- mice develop normally and are 
fertile, with only minor hematologic side effects. This suggests that HRI inhibition may be 
well-tolerated systemically, and provides rationale for the development of small molecule 
HRI inhibitors for use in combination with PI’s and perhaps other proteotoxic stressors such 
as arsenicals.  
In Chapter 4, our study describing Hsp72 as a resistance factor to BZ in bladder 
cancer presents two important future directions. First, this study supports the continued 
development of Hsp72-specific inhibitors for use in cancer therapy, particularly in 
combination with other proteotoxic stress-inducing drugs such as PIs. Multiple research 
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groups are working to achieve this, and inhibitors should become available within a few 
years. Secondly, our data suggest a high incidence of HSPA1A promoter methylation in 
bladder cancer, which may open a therapeutic window for selective targeting of the 
HSPA1B isoform. Although we did not observe a significant correlation between extremely 
low HSPA1A expression and BZ sensitivity, the potential of HSPA1A promoter methylation 
as a biomarker bears further investigation. Because of the multitude of cytoprotective 
functions of Hsp72 (protein folding, anti-apoptosis, lysosomal stability), it would be 
expected that shutting off the HSPA1A promoter and relying exclusively on the HSPA1B 
locus could have significant consequences for a malignant cell. We hope to analyze 
HSPA1A promoter methylation in patient bladder tumor samples in the future, with hopes of 
1) identifying the prevalence, and 2) probing for correlations with outcomes and survival.  
Chapter 5. Because of our unexpected conclusion that Type I HDAC inhibition is 
more effective than HDAC6 inhibition in promoting BZ-induced cell death in solid tumor 
cells, we are now actively pursuing intriguing new data in which HDAC6 inhibition by 
Compound A may effectively reduce solid tumor cell migration and invasion. We are 
currently evaluating Compound A in vitro for its effects on pancreatic and bladder cancer 
cell migration using the traditional scratch assay, and on invasion by chemotactic movement 
through a 3D matrigel chamber. Ultimately, we seek to apply Compound A to a mouse 
model of metastatic bladder cancer developed by other investigators in our group and 
measure circulating tumor cells and metastases with and without Compound A. Presently, 
the clinical usefulness for an anti-metastatic agent would be rather limited because it 
remains difficult to accurately predict which tumors will metastasize. Furthermore, 
administration of an anti-metastatic agent after distant metastases were already established 
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would not be optimal. A scenario would have to arise where metastasis was identified very 
early (perhaps through finding small numbers of circulating tumor cells) and was followed 
by immediate administration of the anti-metastatic agent for a specified duration. 
Alternatively, a well-tolerated anti-metastatic agent could be useful following resection of a 
tumor that displayed aggressive phenotypes but had not yet visibly metastasized. The agent 
could then be administered following surgery in order to prevent the development of 
metastases from the residual un-resectable tumor cells that had already invaded peripheral 
tissue. Despite the challenges just mentioned, the anti-metastatic potential of HDAC6 
inhibition is an important phenotype that may become valuable in the future since selective 
HDAC6 inhibition is thought to be better tolerated systemically than inhibition of Type I 
HDACs. 
 
6.3 Final Discussion 
In an effort to combine my conclusions across all of these projects and tumor types, I 
would like to comment in a broad sense on what my observations have led me to believe 
about the mechanisms that most significantly contribute to proteasome inhibitor-induced 
cytotoxicity. Based on my results, if I were to now rank the three pathways studied in my 
thesis  in terms of their centrality to controlling cellular outcome following PI, they would 
rank in the following order: 1) eIF2α phosphorylation/ translational control, 2) Hsp72 
induction/ heat shock response, and 3) the HDAC6/ aggresome pathway. Here, I discuss 
why I believe this hierarchy to be true. 
Believing that the simplest, most intuitive explanation is often correct, let me build 
on the assumption that the primary consequence of PIs is the bulk accumulation of 
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misfolded proteins with nowhere to go. The goal of the cell is then obviously to stop this 
accumulation, so what is the most efficient way to accomplish this? The simplest 
explanation is to stop making more misfolded proteins. This is why I believe eIF2α 
phosphorylation to be central to determining cellular fate following PI. As protein 
production is shutting down, secondary response mechanisms come into play since the cell 
must handle the misfolded species that had already accumulated. This is where the heat 
shock response (HSR) and chaperones come into play. The cell increases the level of 
chaperones (such as Hsp72) to “sequester” these toxic proteins. Finally, the misfolded 
substrates must be disposed of somehow, but because the proteasome is blocked, the cell 
must utilize an alternative strategy called autophagy.   This simplistic model can be 
conceptualized as a clogged tub filling up with water (Fig 6.1). Now imagine if the 
proteasome is blocked but the cell does not stop protein synthesis when it should. 
Everything else downstream becomes almost irrelevant, presenting essentially 
insurmountable odds for the chaperone network and autophagy. By adopting this 30,000 
foot view of cellular biology, one can “rank” the relative inputs into the PI-induced stress 
response and predict which pathways could be disrupted to best augment the activity of PIs. 
A graphical view of the activation of these essential pathways is provided in Fig. 6.2.   
The most intriguing aspect of intrinsic tumor biology identified over the course of 
my studies has been the discovery that basal phosphorylation levels of eIF2α differ between 
cancer cell lines. I and others in our group have seen this phenomenon in multiple 
pancreatic, bladder, and prostate cancer cells, and I have also spoken with other 
investigators at conferences who had noticed similar phenomena, but had not investigated it  
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Figure 6.1 The “bathtub” effect. Theoretical diagram outlining how 3 critical stress 
response pathways work to relieve the stress caused by proteasome inhibition. 1) 
Proteostasis is maintained by a proteomic balance of synthesis and degradation, or 
inflow/outflow. 2) If the proteasome (outflow) becomes blocked, then the balance is 
disrupted and unwanted proteins accumulate above the tolerated “threshold.” 3) Inflow must 
then be stopped (accomplished by eIF2α phosphorylation turning off protein synthesis, or 
the “faucet”). 4) The cell must now restore proteostasis. Inducible molecular chaperones or 
heat shock proteins (Hsps) sequester or “soak up” the accumulated misfolded proteins. 5) 
The chaperone-misfolded substrate complexes (often coalesced into large aggregates to 
facilitate degradation) are then engulfed, or “scooped up” by autophagosomes (buckets) for 
recycling. Collectively, this effort reduces the levels or misfolded proteins to below the 
threshold, assuming that proteasome activity is soon restored.  
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Figure 6.2 Temporal depiction of the three major systems needed for response to 
proteasome inhibitors. Graphical interpretation of the relative rates of translation, 
induction of the heat shock response, and activation of autophagy following exposure to a PI 
(x-axis = hours post-exposure). Translation repression and the heat shock response are the 
most rapid responses (significant changes within 4-8h), with autophagy activation occurring 
later (12-18h). Following resolution of stress, these systems should begin to move back 
towards steady-state levels (dashed lines). 
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further. My work (Chp. 3) is the first time that this elevated basal phosphorylation has been 
linked to enhanced sensitivity to a chemotherapeutic agent. Because of the centrality of 
eIF2α phosphorylation in mitigating proteoxic stress, this basal phosphorylation status may 
be useful in predicting response to other proteotoxic stress-inducing agents such as 
arsenicals or Hsp90 inhibitors. Additionally, basal eIF2α-P levels could also predict how a  
cell responds to targeted therapeutics against signaling pathways that influence protein 
synthesis such as the Akt/PI3K pathway. 
Presumably Hsp72 induction and especially aggregate handling by HDAC6 would 
be more critical to cells which possessed constitutive, un-inducible eIF2α phosphorylation 
because levels of misfolded and aggregated proteins would be higher due to continued 
translation. However, I noticed roughly similar levels of Hsp72 induction irrespective of 
their phospho-eIF2α status; likewise, HDAC6 inhibition provided little sensitization to BZ 
in cells with constitutive, un-inducible eIF2α phosphorylation (with the exception of T3M4). 
Because of the underwhelming effects of HDAC6 inhibition in my hands, and because of 
recent findings in the literature, I believe that instead of targeting the aggresome pathway, 
more direct inhibitors of autophagy would be much more effective in combination with PIs. 
Constitutively high autophagy has been found in pancreatic cancer (124), and this autophagy 
was shown to be required for tumorigenesis. Activated Ras has also been found to drive 
increased basal autophagy to promote tumorigenesis, which may explain why this system is 
highly activated in pancreatic cancers (5). My data also suggest that basal autophagy 
correlates with basal eIF2α phosphorylation, and in cells where eIF2α is un-inducible, 
autophagy appears to be un-inducible as well. The mechanistic link between eIF2α and 
autophagy is presently unclear, and our group has had difficulty in identifying a stress-
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responsive transcription factor that drives ATG gene upregulation. A scenario can be 
imagined where activated Ras drives metabolic changes that activate the GCN2 kinase and 
raise basal eIF2α phosphorylation, which then signals the up-regulation of autophagy to 
maintain energy for the Ras-driven cell.  
Indeed other plausible mechanisms not examined in this thesis may also influence 
the cytotoxicity of PIs in cancer cells. Two such possibilities, known as EMT (epithelial-to-
mesenchymal transition) and mitochondrial priming, involve characteristics of cancer cells 
that have the potential to convey pan-resistance to a broad spectrum of chemotherapeutic 
agents. EMT collectively refers to a reversible process  through which cells transition from 
an epithelial morphology with tight cell-cell interactions into more fibroblast-like cells with 
decreased polarity and cell-cell interactions. It is hypothesized that this transition confers a 
more metastatic phenotype to cancer cells, allowing them to break free of the primary tumor 
and invade surrounding tissue to enter circulation. EMT has also been associated with 
broad-spectrum drug resistance; indeed recent work from our group has indicated that a 
more mesenchymal phenotype leads to resistance to standard chemotherapeutic agents in 
pancreatic cancer preclinical models (98). In this study by Arumugam, et al., many of the 
same cell lines that I found sensitive to BZ were also more sensitive to the conventional 
chemotherapeutic agents gemcitabine, cisplatin, and 5-fluorouracil (5-FU). In addition, by 
reversing EMT through genetic silencing of a pro-mesenchymal transcription factor known 
as Zeb-1, we were able to sensitize resistant, mesenchymal Suit2 cells to BZ. We did not 
evaluate the P-eIF2α status of the Zeb-1 silenced cells however, which is needed to conclude 
if EMT affects basal phosphorylation levels or translational control in any way. In our 
hands, mesenchymal cells do not have appear to have lower rates of translation, so it is 
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likely that Zeb-1 knockdown promotes BZ-induced cell death by other mechanisms. 
Through unpublished work from our group and the work of others, inhibition of Class I 
HDACs may be another strategy to reverse EMT (184). This could be an important 
explanation for why SNDX-275 was more potent than Compound A in sensitizing cells to 
BZ. Overall, the relationship between EMT and protein quality control networks bears 
further exploration. 
 The idea of mitochondrial priming is relatively new and has been developed by 
seminal work from the laboratory of Anthony Letai at the Dana-Farber Cancer Institute. 
Through direct introduction of BH3-only pro-apoptotic peptides, his group has found that 
certain cancer cells are intrinsically resistant to apoptosis, whereas other cancer cells are 
more “primed” and readily undergo apoptosis. This “priming” refers to the relative 
“proximity to the apoptotic threshold” of mitochondria isolated from cancer cells as 
measured by their ability to undergo mitochondrial outer membrane permeabilization 
(MOMP) upon direct exposure to PUMA, BMF, and BIM BH3-only peptides  (185). This is 
an attractive explanation for broad-spectrum drug resistance in cancer, and although not 
tested here, could be another contributing factor to the BZ sensitivity/resistance of the 
pancreatic and bladder cancer cells that were studied.   
 In conclusion, I hope that this thesis provides key contributions to understanding 
how proteasome inhibitors function as anti-cancer agents, and how cancer cell heterogeneity 
influences their efficacy. A final model summarizing my view of the cellular response to 
proteasome inhibition and suggested locations for therapeutic targeting is presented in Fig. 
6.3. It is an exciting time for cancer research, and I am grateful that I was able to spend five 
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and half years of my life addressing perhaps the biggest biomedical challenge of my 
generation at such a world-class institution. Much is left to be uncovered, and as I have 
 stood on the shoulders of those before me, I hope that this work provides a solid foundation 
for others to come. 
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Figure 6.3 Overall model depicting the various inputs into cellular outcome following 
proteasome inhibition. Left, eIF2α-mediated translational repression plays the most 
essential role in preventing downstream proteotoxicity, and may potentially play a role in 
activating autophagy as a secondary degradation system. Right, activation of the heat shock 
response attempts to inhibits aggregate accumulation and toxicity by refolding or and 
shielding hydrophobic residues from the cytosol and other proteins. Hsps may also play a 
role in presenting substrates to autophagy, and may also ensure functionality of autophagy 
through stabilization of the lysosomal membrane. Finally, HDAC6 inhibition affects only a 
single input (handling of aggregates for degradation by autophagy), whereas Class I HDAC 
inhibition may affect multiple, which may explain why Class I inhibition sensitize cells to 
BZ better than HDAC6 inhibition. Orange lightning bolts indicate the best areas for 
developing therapeutic strategies to enhance the activity of PIs. 
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